 
 
A Phase 2 Double -Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee P ain of 
CGS-200-1 (1% Capsaicin Topical Liquid), CGS -200-5 (5% Capsaicin Topical Liquid), and CGS -200-0 
(Vehicle, No Capsaicin) ‚Äì Protocol  
  
Protocol Number:  VZU00025  
Protocol Date : 1-AUGUST -2018  
[STUDY_ID_REMOVED]  

CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 1 Protocol Title:  A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects 
on Osteoarthritic Knee Pain of CGS -200-1 (1% Capsaicin Topical Liquid), 
CGS-200-5 (5% Capsaicin Topical Liquid), and CGS -200-0 (Vehicle, No 
Capsaicin)   
 
Protocol Number:  VZU00025  
 
Version No./Date:  5.0 / 1-AUGUST -2018 
 
Study Drug:  CGS-200-5 (Capsaicin 5% Topical Liquid);  
CGS-200-1 (Capsaicin 1 % Topical Liquid); and, 
CGS-200-0 (Investigational Drug Product Vehicle, 0% Capsaicin)  
  
IND #: 138684 
 
Sponsor:  
Vizuri Health Sciences LLC  
12500 Fair Lakes Circle   
Suite 450 
Fairfax, VA 22033  
Phone: 301 -728-0178 
 Medical Monitor  
William S. Aronstein, Ph.D., M.D., F.A.C.P.  
Vice President, Medical Affairs  
CTI Clinical  Trial & Consulting Services  
100 E. RiverCenter Blvd  
Covington, KY 41011  
Phone: 1-800-873-5695 
 
 
 
 
 
 
 
 
 
 
 
 
Confidential and Proprietary  
 
This protocol is a confidential communication document of Vizuri Health Sciences LLC. The recipient of this 
document agrees not to disclose the information contained herein to others without prior written authorization of 
Vizuri Health Sciences LLC. except  that this document may be disclosed to appropriate Institutional Review 
Boards/Independent Ethics Committees or duly authorized representatives of Regulatory authorities such as the United 
States (U.S.) Food and Drug Administration, European Medicines Age ncy, or other cognizant authorities worldwide 
under the condition that they maintain confidentiality.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 2 Investigator Agreement  
I confirm that I have re ad and understood this protocol  and agree to conduct this study as outlined 
in the protocol and other information supplied to me. I agree to conduct this study in compliance 
with Good Clinical Practice (GCP) standards as defined by the International Conference on 
Harmonization (ICH) Gui deline for Good Clinical Practice, the ethical principles of the 
Declaration of Helsinki, all applicable national, state and local regulations, as well as the 
requirements of the appropriate Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and any other institutional requirements.  
Principal Investigator:  
Signature  Date 
Name (please type or print)  
Institution  
Address 
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 3 STUDY SYNOPSIS  
Sponsor:  Vizuri Health Sciences LLC  
12500 Fair Lakes Circle   
Suite 450 
Fairfax, VA 22033  
Protocol Title:  A Phase 2 Double -Blind Clinical Trial to Examine the Comparative 
Effects on Osteoarthritic Knee Pain of CGS -200-1 (1% Capsaicin 
Topical Liquid), CGS -200-5 (5% Capsaicin Topical Liquid), and 
CGS-200-0 (Vehicle, No Capsaicin)  
Protocol Number : VZU0002 5 
Study Phase : Phase 2 
Study Endpoints:  
  The Primary Efficacy endpoint of this study will be to examine the 
extent of reduction in the WOMAC pain  score, relative to baseline, 
provided by once daily, one -hour application of Vehicle 
(CGS-200-0), CGS-200-1, and CGS-200-5 at the following 
assessment times:  
 
Baseline: < 30 minutes prior to first daily application  
Day 35  31 Days (+/ - 3 days) after fourth daily application  
 
and based thereon to determine whether the responses for treatment 
with CGS -200-1 and CGS-200-05 are significantly different from 
Vehicle (CGS-200-0) and from each other at the primary endpoint 
time.  
 
The Primary Safety  endpoints  will be: 
 
(1) The application of the study drug does not produce skin 
reactions (erythema, scaling, pruritus, or other) to a degree 
that is clinically of concern. Scoring of eryth ema and scaling 
at the application sites and of pruritus will be assessed per the 
scoring systems in  Appendix F. 
 
(2) No SAE‚Äôs either possibly, probably, or definitely associated 
with study treatments.  
 
(3) Safety labs (hematology, serum chemistry and urinalysis ) do 
not produce other than minimal ‚Äì mild toxicities (Grade 1 or 
Grade 2). Scoring of clinical, hematological and urinalysis out 
of range fin dings for toxicity grading will be per  Appendix B. 
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 4  Secondary Efficacy endpoints will be: 
 
(1) To examine the extent of reduction in the WOMAC pain  score, 
relative to baseline, provided by once daily, one -hour 
application of Vehicle (CGS -200-0), CGS-200-1 and 
CGS-200-5 at the following assessment times:  
 
Baseline: < 30 minutes prior to first daily application  
Day 5   24 hrs (+/- 3) after last of the 4 daily applications  
Day 19  15 days (+/ - 3) after last of the 4 daily applications  
Day 64  60 days (+/ - 3) after the last of 4 daily applications  
Day 94  90 days (+/ - 3) after the last of 4 daily applications  
 
(2) Day 5, 19, 35, 64, and 94 W OMAC scores on the stiffness and 
function subscales as well as total WOMAC score  (including 
the WOMAC pain score).  
 
 
Secondary Safety  endpoints will be:  
 
(1) The distribution by study arms of specific Adverse Events  
(AEs) (e.g ., local application site reactions, and other AEs 
(inclusive of findings for hematology and serum chemistry )).  
(2) Evaluate the amount of concomitant pain medications used 
overtime 
 
Tolerability  endpoints (which are secondary in nature) will be:  
 
(1) The application of study drug does not produce burning -
stinging pain (‚ÄúBSP‚Äù) at the application site to a degree that is 
not acceptable to the subject. BSP at the application site, this 
will be assessed using a 0 ‚Äì 10 NRS sca le without guideposts. 
‚ÄúAcceptability‚Äù of BSP will be queried per subject at the end 
of each application period.  
 
(2) The application of the study drug does not produce pruritus 
during application or in the 24 hrs post -application to a degree 
that is not accep table to the subject or, if bothersome to the 
subject, cannot be managed by application of ice or a cold pack 
or compress  
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 5 Study Duration  13-14 weeks for each subject, excluding screening.  
Study Design:  This is a multi -center, randomized, double -blind clinical trial in subjects 
with OA according to the 1986 American College of Rheumatology 
(ACR) criteria. There will be with three study arms:  
 
Arm 1  CGS-200-0 (Investigational Drug Product Vehicle)  
Arm 2  CGS-200-1 (1% Capsaicin in CGS -200 vehicle)  
Arm 3  CGS-200-5 (5% Capsaicin in CGS -200 vehicle)  
 
Each Arm will enroll 40 evaluable subjects, for a total of 120 evaluable 
subjects in this study. Subjects that give Informed Consent to participate 
and who are deemed after screening to be eligible to participate will be 
randomized to one of the three study Arms.  
 
Subjects will receive the Arm -appropriate treatment as a topical 
application over the frontal aspect of the knee(s)  once daily on four 
consecutive days. The applications will be at the clinic but by the 
subject under supervision of clinic personnel. Wearing gloves 
supplied by the clinic staff, the subject will apply the study drug on 
and around the knee covering a 10cm by 10cm area. The application 
will be left in place for 60  (up to 65) minutes and then washed off at 
the clinic by clinic personnel.  The amount of Investigational Drug 
Product to be applied is estimated to be approximately 0.13 mL based 
on experience in prior studies. Even though both knee(s) will receive 
application of study test materials, with regard to reduction in 
WOMAC pain and VAS pain score associated with study treatments, 
only one knee will be indicated as the ‚ÄúStudy Knee‚Äù. This will be the 
knee with the highest WOMAC pain score at baseline. If both knees 
have equal WOMAC pain scores at baseline, then the right knee will 
be considered the ‚ÄúStudy Knee‚Äù with regard to WOMAC pain and 
VAS pain score reduction.   
 
The Investigators, all site staff, study subjects and Clinical Research 
Organization (CRO) personnel (except for the Medical Monitor 
providing safety oversight) directly involved in the study will remain 
blinded to the treatment assignment throughout the trial.  
 
Estimated No. of 
Subjects:  Total 120 evaluable subjects : 40 subjects will be allocated to each 
study Arm. An allowance of up to 10 subjects per Arm is to be 
provided for dropouts whose withdrawal is not due to lack of study 
drug tolerability).   
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 6 Inclusion/Exclusion  
Criteria:  Inclusion Criteria  
The subject must meet all of the following:  
1. Able to comprehend the informed consent form (ICF) and provide 
Informed Consent, and capable of complying with all study 
procedures;  
2. Male or female, 35 years of age to 75 years;  
3. OA of at least one knee  according to 1986 ACR Class ification 
Criteria; 
4. OA of at least one knee  must be confirmed by tibiofemoral joint 
radiographs obtained within the past 6 months;  
5. Rheumatoid factor ( RF) negative and Erythrocyte sedimentation rate 
(ESR) <40 mm/hr;  
6. Chronic knee pain in at least one knee for > 3 months;  
7. WOMAC pain score of > 250 (using VAS WOMAC format) at  
screening , and at baseline,  in at least one knee ; 
8. Knee pain score of > 5 on the NRS pain scale at  screening , and at 
baseline, in at least one knee;  
9. Knee pain is not potentially due to acute trauma unrelated to OA 
(no acute traumatic knee injury in medical history);  
10. No burning -stinging pain, unrelated to subject‚Äôs knee pain, at 
intended site of application;  
11. Knee pain must be greater than pain in any other part of subject‚Äôs 
body; 
12. ACR global functional status I, II, or III (excluding IV);  
13. If female, subject must be past childbearing age or otherwise must 
test negative for pregnancy. Males and females must agree to use 
effective birth control for at least 30 days after last dose of study  
drug. 
 
Exclusion Criteria  
 
The subject must not have any of the following:  
1. Spontaneously improving or rapidly deteriorating OA of the knee;  
2. Rheumatoid or psoriatic arthritis, or a form of arthritis (e.g. gout, 
pseudogout), Paget‚Äôs disease of bone, or any other disease affecting 
the joints that are inconsistent with a diagnosis of idiopathic OA;  
3. Use of topical, oral, or injectable steroids for 1 month prior to 
screening, or intraarticular visco -supplementation within 3 months 
prior to screening;  
4. Used any capsaicin -containing product on or in the vicinity of the 
knee within 4 weeks prior to screening;   
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 7 5. Used topically applied products (including emollients or 
moisturizers) on or in the vicinity of the knees or shaved the knees 
within 2 days prior to the first application of study drug; or an open 
wound near the knee; cutaneous erythema or edema; any 
inflammatory skin lesions such as eczema or psoriasis; cutaneous 
infections; or any other compromise of the skin;  
6. A history of sensitivity to topical substanc es inclusive of OTC 
topical analgesics;  
7. Labile or poorly controlled hypertension ; 
8. Significant cardiovascular, renal, or other diseases or conditions, or 
laboratory or other test abnormalities that, in the opinion of the 
Investigator, would contraindicate p articipation in the trial;  
9. A psychiatric disorder or significant anxiety or depression that 
could interfere with the subject‚Äôs compliance with study procedures 
or completion of the study;  
10. Requires daytime use of medications or substances (alcohol, 
benzodiazepines, barbiturates, muscle relaxants, tranquilizers, 
hypnotics) that could diminish their cognitive ability to comply 
with study procedures;  
11. A history of drug or alcohol abuse within one year prior to 
screening;  
12. Requires or anticipates any surgical proc edure within 3 months 
prior to screening, has had surgery on the affected joint within 
6 months prior to screening, has a prosthesis  in either knee , or 
would require surgery while participating in the trial;  
13. Pregnant or nursing;  
14. Treated with an investiga tional drug, device or therapy within 
30 days prior to screening . 
15. Body mass index  greater than 45 kg/m2 
16. Skin on or near knee is broken or damaged or if there is an open 
wound on or near the knee . 
 
Investigational  
Product and Mode of 
Administration:  CGS-200-1 and CGS-200-5 are topical analgesic liquids intended for 
application to intact, non -irritated skin in adults with musculo -skeletal 
pain inclusive of OA of the hands, wrists, elbows, or knees for the 
relief of pain, reduction of st iffness, and increased functional activity.  
CGS-200-1 is a multi -component formulation in which the active 
ingredient for the intended therapeutic effect is 1% capsaicin (wt/wt). 
CGS-200-5 is a multi -component formulation in which the active 
ingredient for the intended therapeutic effect is 5% capsaicin (wt/wt). 
Placebo for this study is the vehicle (designated CGS -200-0) which 
has no capsaicin.  
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 8 Study Monitoring  This study will be monitored by CRO personnel.  
 
An electronic case report form ( eCRF) will be used for this study  
Statistical Analysis  Primary Efficacy Endpoint  
The group mean LMS difference between each Active Treatment Arm 
and the Vehicle Arm for the WOMAC pain score at Day 35 will be 
tested for significance of difference at a significance value of p < 0.05.  
 
Secondary Efficacy Endpoint s 
The group mean LMS diff erence between each Active Treatment Arm 
and the Vehicle Arm for the WOMAC stiffness, function and total 
score at Days 5, 19, 35, 64, and 94 will be tested for significance of 
difference at a significance value of p < 0.05. 
 
Also, the group mean reduction in OA knee pain score on a 100 mm 
VAS scale for each active treatment arm will be compared to the 
vehicle arm and tested for significance of difference at a significance 
value of p < 0.05. 
 
For dose-response estimation :  
 
The group mean LMS difference between the 5% and the 1% Active 
Treatment Arms for the WOMAC pain, stiffness, function and total 
score at Day 35 will be tested for significance of difference at a 
significance value of p < 0.05. 
 
Primary Safety Endpoint  
This will be analyzed using descriptive statistics in tabular form.  
 
Secondary Safety Endpoint  
This will be analyzed using descriptive statistics in tabular form.  
 
Tolerability Endpoint  
This will be analyzed using descriptive statistics in tabular form.  
 
Other 
Sponsor may elect to conduct appropriate post -hoc analyses.  
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 9 SIGNATURE PAGE  
Product name:   CGS-200-1 (Capsaicin 1% Topical Liquid)  
CGS-200-5 (Capsaicin 5% Topical Liquid)  
CGS-200-0 (Vehicle, 0% Capsaicin, placebo)  
 
Protocol Number:  VZU00025  
 
The signatures of the representatives below constitute their approval of this protocol and provide the 
necessary assurances that this study will be conducted according to all stipulations stated in the protoc ol, 
including all statements as to confidentiality. It is also agreed that the study will not be initiated without the 
approval of an appropriate Institutional Review Board or Ethics Review Committee.  
 
Internal personnel (Vizuri Health Sciences LLC):  
 
 
 
 
 
John Todhunter, PhD  
Chief Scientific Officer  
Head of Regulatory Affairs  Signature   Date 
 
 
 
         
Margaret Fleming  
Independent Clinical Operations Consultant  Signature   Date 
 
 
 
 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
STUDY SYNOPSIS  (continued)  
FINAL / Version 5.0 1-AUGUST -2018 Page 10 TABLE OF CONTENTS
Page 
 
LIST OF TABLES ................................ ................................ ................................ ................................ .......................  13 
LIST OF FIGURES  ................................ ................................ ................................ ................................ .....................  14 
LIST OF APPE NDICES ................................ ................................ ................................ ................................ ............. 15 
1.0 INTRODUCTION  ................................ ................................ ................................ ................................  18 
1.1 BACKGROUND AND RATIONALE  ................................ ................................ ................................ .. 18 
1.2 NONCLINICAL TOXICOLOGY SUMMARY  ................................ ................................ ....................  23 
1.3 PREVIOUS CLINICAL EXPERIENCE  ................................ ................................ ...............................  27 
1.4 SUMMARY OF SAFETY DATA  ................................ ................................ ................................ ......... 32 
1.4.1  Possible Risks  ................................ ................................ ................................ ...............  35 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ ........................  36 
2.1 PRIMARY ENDPOINTS  ................................ ................................ ................................ ......................  36 
2.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ................  37 
3.0 STUDY DESIGN  ................................ ................................ ................................ ................................ .. 39 
3.1 OVERALL STUDY DESIGN  ................................ ................................ ................................ ...............  39 
3.2 DOSE LIMITING TOXICITY  ................................ ................................ ................................ .............. 39 
4.0 SELECTION AND WITHDRAWAL OF SUBJECTS  ................................ ................................ ..... 41 
4.1 INCLUSION/ EXCLUSION CRITERIA:  ................................ ................................ .............................  41 
4.1.1  Inclusion Criteria:  ................................ ................................ ................................ ......... 41 
4.1.2  Exclusion Criteria:  ................................ ................................ ................................ ........ 42 
4.2 REPLACEMENT OF SUBJECTS  ................................ ................................ ................................ ......... 43 
5.0 STUDY TREATMENT ................................ ................................ ................................ ........................  44 
5.1 CGS-200-1, CGS-200-5, AND CGS -200-0 (VEHICLE)  ................................ ................................ ...... 44 
5.1.1  Formulation  ................................ ................................ ................................ ...................  44 
5.1.2  Packaging, Labeling and Storage  ................................ ................................ ..................  45 
5.1.3  Rationale for Dose Selection  ................................ ................................ .........................  45 
5.1.4  Dosage and Administration  ................................ ................................ ...........................  46 
5.1.5  Reporting Product Defects  ................................ ................................ ............................  48 
5.2 CONCURRENT MEDICATIONS  ................................ ................................ ................................ ........ 48 
5.2.1 Allowed Regimens  ................................ ................................ ................................ ........ 48 
5.2.2  Prohibited Medications  ................................ ................................ ................................ . 48 
5.3 PROHIBITED PROCEDURES  ................................ ................................ ................................ ............. 49 
6.0 STUDY PROCEDURES  ................................ ................................ ................................ ......................  50 
6.1 SCREENING VISIT  ................................ ................................ ................................ ..............................  50 
6.2 ON-TREATMENT EVALUATIONS:  ................................ ................................ ................................ .. 51 
6.3 FOLLOW -UP PERIOD EVALUATIONS  ................................ ................................ ............................  52 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
TABLE OF CONTENTS  (continued)  
Page 
 
FINAL / Version 5.0 1-AUGUST -2018 Page 11 6.4 BIRTH CONTROL REQUIREMENTS  ................................ ................................ ................................  52 
6.5 ASSESSMENTS AT TIME OF SAE, EARLY TERMINATION OR UNSCHEDULED VISIT  ......... 53 
6.6 STUDY BLOOD DRAW VOLUME  ................................ ................................ ................................ ..... 54 
6.7 RECOMMENDATIONS FOR MANAGEMENT OF POTENTIAL TOXICITIES  .............................  54 
6.7.1  Allergic Reaction, Burning, or Pruritus  ................................ ................................ ........ 54 
6.8 CONCOMITANT MEDICATIONS/RESCUE MEDICATIONS  ................................ .........................  54 
6.9 STOPPING CRITERIA  ................................ ................................ ................................ .........................  55 
6.9.1  Criteria for Adverse Event Assessment  ................................ ................................ ........ 55 
6.9.2  General Criteria for Stopping Study Drug  ................................ ................................ .... 55 
6.9.3  Stopping Criteria  ................................ ................................ ................................ ........... 55 
6.10 WITHDRAWAL OF SUBJECTS FROM STUDY  ................................ ................................ ...............  55 
7.0 CLINICAL ACTIVITY  ................................ ................................ ................................ .......................  57 
8.0 SAFETY ASSESSMENTS  ................................ ................................ ................................ ..................  58 
8.1 ADVERSE EVENTS  ................................ ................................ ................................ .............................  58 
8.1.1  Definitions ................................ ................................ ................................ .....................  58 
8.1.2  Reporting to the Sponsor  ................................ ................................ ...............................  59 
8.1.3  Investigator Evaluation of Adverse Events  ................................ ................................ ... 59 
8.1.4  Follow-up of Adverse Events ................................ ................................ ........................  62 
8.1.5  Post Study SAEs  ................................ ................................ ................................ ........... 62 
8.1.6  Reporting to the Institutional Review Board/Independent Ethics Committee  .............. 62 
8.2 LABORATORY TESTS  ................................ ................................ ................................ ........................  63 
9.0 DATA ANALYSIS METHODS  ................................ ................................ ................................ .......... 64 
9.1 DETERMINATION OF SAMPLE SIZE  ................................ ................................ ...............................  64 
9.2 RANDOMIZATION AND BLINDING  ................................ ................................ ................................  64 
9.3 ANALYSIS SETS  ................................ ................................ ................................ ................................ .. 64 
9.4 SUBJECT ACCOUNTABILITY  ................................ ................................ ................................ ........... 64 
9.5 STATISTICAL METHODS  ................................ ................................ ................................ ..................  65 
9.5.1  Analysis of Demographic and Subject Characteristics  ................................ .................  65 
9.5.2  Treatment Administration/Compliance  ................................ ................................ ......... 65 
9.5.3  Efficacy Analyses  ................................ ................................ ................................ ......... 65 
9.5.4  Tolerability Analyses  ................................ ................................ ................................ .... 66 
9.5.5  Safety Analyses  ................................ ................................ ................................ ............. 67 
9.5.6  Vital Signs  ................................ ................................ ................................ .....................  67 
9.5.7  Interim Analyses  ................................ ................................ ................................ ........... 68 
9.5.8  Procedures for Missing, Unused and Spurious Data  ................................ .....................  68 
9.5.9  Rules for Excluding Subjects from Analysis  ................................ ................................  69 
9.5.10  Procedures for Reporting Deviations from Original Statistical Plan  ............................  69 
10.0 CLINICAL STUDY ADMINISTRATION  ................................ ................................ ........................  70 
10.1 INFORMED CONSENT ................................ ................................ ................................ ........................  70 
10.2 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE REVIEW AND 
APPROVAL  ................................ ................................ ................................ ................................ ........... 70 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
TABLE OF CONTENTS  (continued)  
Page 
 
FINAL / Version 5.0 1-AUGUST -2018 Page 12 10.3 PROTOCOL COMPLIANCE  ................................ ................................ ................................ ................  71 
10.4 PROTOCOL REVISIONS  ................................ ................................ ................................ .....................  71 
10.5 DATA COLLECTION  ................................ ................................ ................................ ...........................  71 
10.6 DATA MANAGEMENT RESPONSIBILITIES  ................................ ................................ ...................  72 
10.7 STUDY MONITORING  ................................ ................................ ................................ ........................  73 
10.8 DRUG ACCOUNTABILITY  ................................ ................................ ................................ ................  74 
10.9 RETENTION OF RECORDS  ................................ ................................ ................................ ................  74 
10.10 FINANCIAL DISCLOSURE  ................................ ................................ ................................ .................  75 
10.11  PUBLICATION POLICY  ................................ ................................ ................................ ......................  75 
10.12  STUDY OR STUDY SITE TERMINATION  ................................ ................................ ........................  75 
11.0 REFERENCES  ................................ ................................ ................................ ................................ ..... 77 
APPENDICES  ................................ ................................ ................................ ................................ ............................  79 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 13 LIST OF TABLES  
 
Page 
 
Table 1‚Äì1. Differences in Latin American and European Placebo Responses and Corresponding Latin 
American and E uropean Responses to Active Treatment (Source: Study VZU00023)  ......................  22 
Table 1‚Äì2. Comparison of CGS -125-5 and CGS -200-5 Composition  ................................ ................................ .. 23 
Table 1‚Äì3. Number of Subjects with BSP > 5 At Times After CGS -200-5 and CGS -200-10 Application in 
Study VZU00020  ................................ ................................ ................................ ................................  27 
Table 6‚Äì1 Screening Procedures  ................................ ................................ ................................ ..........................  50 
Table 6‚Äì2 On Treatment Evaluations  ................................ ................................ ................................ ...................  51 
Table 6‚Äì3 Follow-up Period Evaluations  ................................ ................................ ................................ ............. 52 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 14 LIST OF FIGURES  
 
Page 
 
Figure 1‚Äì1. Group Mean NRS Pain as Percent of Baseline  ................................ ................................ ....................  30 
Figure 1‚Äì2. Group Mean WOMAC Pain as Percent of Baseline  ................................ ................................ ............ 30 
Figure 1‚Äì3. U.S. Conducted OTC Study Vehicle (Placebo) Response Superimposed on Vehicle and 
CGS-200-5 responses in Dominican Republic Conducted Study VZU00023  ................................ .... 31 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 15 LIST OF APPENDICES  
 
 
Appendix A   Laboratory Tests  
Appendix B   Rheumatology Common Toxicity Criteria V2.0  
Appendix C   Schedule of Events  
Appendix D   Exploratory Assessment of Osteoarthritis Knee Pain  
Appendix E   VAS OA KNEE PAIN  
Appendix F   Assessment of Burning / Stinging Pain  
Appendix G   Assessment of Signs and Symptoms  
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 16 LIST OF ABBRE VIATIONS  
 
 
ACR American College of Rheumatology  
AE Adverse Event  
ALK Alkaline phosphokinase  
ALT Alanine aminotransferase  
AST Aspartate aminotransferase  
AUC Area Under the Curve  
BP Blood pressure  
BPM Beats per minute  
BSP Burning stinging pain  
BUN Blood urea nitrogen  
C Celsius 
CBC Complete blood count  
CHO Chinese Hamster Ovary  
cm Centimeter  
Cmax Maximum concentration in serum  
CNS Central Nervous System 
CPK Creatine phosphokinase  
CRO Contract Research Organization  
dL Deciliter 
DLT Dose-limiting toxicity  
DR Dominican Republic  
ECG Electrocardiogram  
eCRF Electronic case report form  
ESR Erythrocyte sedimentation rate  
EULAR European League Against Rheumatism  
FSH Follicle-stimulating hormone  
FOB Functional Observation Battery  
g Gram 
GCP Good Clinical Practice  
GGT Gamma-glutamyl transpeptidase  
Hgb Hemoglobin  
HPLC High-performance liquid chromatography  
hr Hour 
HR Heart rate  
ICF  Informed Consent Form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IgM Immunoglo bulin M 
IND Investigational New Drug  
IRB Institutional Review Board  
ITT Intent-to-treat 
kg Kilogram  
L Liter 
LDH Lactate dehydrogenase  
LLOQ Lower limit of quantification  
LSM Least Mean Squares  
MCH Mean corpuscular hemoglobin  
MCHC Mean corpuscular hemoglobin concentration  
MCV Mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
¬µg Microgram 
mg Milligram  
CONFIDENTIAL  Vizuri Health Science s LLC. 
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
LIST OF ABBREVIATIONS (continued)  
 
FINAL / Version 5.0 1-AUGUST -2018 Page 17 min Minute 
mITT Modified Intent -to-Treat 
mL Milliliter 
¬µL Microliter 
mm Millimeter  
NRS Numeric Rating Scale  
NSAID Non-steroidal anti-inflammatory drug  
OA Osteoarthritis  
OAKP Osteoarthritis knee pain  
OTC Over the counter  
PE Physical examination  
PI Principal Investigator  
RBC Red blood cell  
RCTC Rheumatology Common Toxicity Criteria  
RDC Remote data capture  
RF Rheumatoid factor 
RR Respiratory rate  
SAE Serious adverse event  
SAF Safety 
SF Synovial fluid  
SOP Standard Operating Procedure  
T Temperature  
TEAE Treatment -emergent adverse event  
TFM Tentative Final Monograph  
Tmax Time to maximum effect  
UA Urinalysis  
UCL Upper confidence limit  
ULN Upper limit of normal  
U.S. United States  
VAS Visual Analog Scale  
WBC White blood count  
WHO World Health Organization  
WOMAC  Western Ontario and McMaster Universities Index of Osteoarthritis  
wt Weight 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 18 1.0 INTRODUCTION  
1.1 BACKGROUND AND RATIONALE  
The prevalence of arthritis in the general population is 21% overall, or approximately 
46.4 million adults in the United States (U.S.) .[1] Most of individuals are likely to have 
osteoarthritis (OA),  which is a very common disease.  It is the third most common 
diagnosis made by primary care physicians in older patients and is the most common 
condition involving the knee.  Significant knee pain affects about one quarter of the 
population that are 55 or o lder, and half of these individuals have radiographic evidence 
of OA and a quarter have some degree of disability.  The risk of developing OA is 
related to advancing age, female sex, obesity, trauma, a family history and other factors.  
In 1986, the American College of Rheumatology (ACR) published classificat ion 
criteria for OA of the knee.[2] Classification criteria are not diagnostic criteria, although 
they are often used as such by clinicians.  The criteria are useful in clinical re search, 
including clinical trials, to provide a uniform population for study.  The classification 
criteria are shown in the table below.  
Clinical and laboratory  Clinical and radiographic  Clinical 
Knee pain  
 + 
At least 5 of 9:  
 Age >50 years  
 Stiffness <30 minutes  
 Crepitus 
 Bony tenderness  
 Bony enlargement  
 No palpable warmth  
 ESR <40 mm/hr  
 RF <1:40  
 Synovial fluid signs of OA  Knee pain  
 + 
At least 1 of 3:  
 Age >50 years  
 Stiffness <30 minutes  
 Crepitus 
 + 
 Osteophytes  
 Knee pain  
 + 
At least 3 of 6:  
 Age >50 years  
 Stiffness <30 minutes  
 Crepitus 
 Bony tenderness  
 Bony enlargement  
 No palpable warmth  
 
 
ESR = Erythrocyte sedimentation rate; RF = rheumatoid factor; Synovial fluid (SF) signs of OA are clear, viscous 
fluid or SF white blood  cell count <2,000/mm3 
The European League Against Rheumatism (EULAR) has developed guidelines for the 
diagnosis of OA.[3] During the development of the guidelines, they found that 3 
symptoms (persistent knee pain, morning stiffness, and decreased function) and 3 signs 
(crepitus, restricted movement, and bony enlargement) were most important in the 
diagnosis.  The more symptoms and signs, the more certain is the diagnosis.  While 
diagnostic guidelines are useful in patient care, it will be necessary to use classification 
criteria in this clinical trial.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 19 The pathogenesis of OA remains unclear; however, certain types of OA show familial 
aggregation, and excessive load on joints may play a role.  In addition, over the years, 
there has been some consideration as to whether OA involves inflammation and 
whether it is a primary driver of the development of OA or whethe r trauma or other 
factors produce damage that results in secondary inflammation.  
Whatever the pathogenetic mechanisms may be, OA is a progressive disorder that 
results in disability.  There is a great unmet medical need for more effective treatments 
for OA. Better treatment of the pain of OA has the potential for postponing disability 
and improving health -related quality of life  
Current standard of care for OA may include non -pharmacologic interventions such as 
exercise, weight loss, appropriate insoles, wal king aids, patellar taping in a medial 
direction, thermal treatments, tai chi, psychosocial interventions and self -management 
programs .[4] Pharmacologic agents that can be used include acetaminophen, non -
steroidal anti -inflammatory drugs (NSAID) given orally or t opically, tramadol, 
duloxetine, and intra -articular hyaluronate, corticosteroids, or injections.  In addition, 
opioids may be considered in those who respond inadequately to initial interventions.  
In patients who have failed medical therapy or are not willi ng to undergo surgery, or 
for whom joint replacement surgery is contraindicated, opioid therapy is strongly 
recommended.  
Acetaminophen carries a risk of liver damage.  The use of oral NSAIDs is associated 
with a potential for gastric and intestinal ulcerat ion and high doses of NSAIDs have 
been associated with an elevated risk of cardiac problems.  The intent of topical 
NSAIDs is to reduce the systemic levels of these drugs (thereby lowering the risk of 
gastro-intestinal damage) while providing for a therapeu tically effective level in and 
around the affected area.  However, these products ‚Äì whether oral or topical ‚Äì require 
regular daily use and administration more than once daily.  The use of any opiate -
containing product poses a risk for addiction or diversion .  
There is therefore considerable unmet medical need for a treatment of OA knee pain 
(OAKP) that does not require regular daily use, does not carry the gastro -intestinal risks 
of NSAIDs or the liver risks of acetaminophen or the addiction / diversion risk s of 
opiates, and can safely provide long lasting pain relief after a brief course of treatment.   
&21),'(17,$/ 9L]XUL+HDOWK6FLHQFHV//&
 &*6DQG&*6YV&*69HKLFOH
3URWRFRO9=8 

),1$/9HUVLRQ$8*867 3DJH6SRQVRU¬∂VH[SHULHQFHVXJJHVWV WKDWFDSVDLFLQDSULQFLSDODFWLY HFRPSRQHQWLQFKLOL
SHSSHUVPD\SURYLGHH[WHQGHGD QDOJHVLDIRU2$.3DIWHUWRSLFDO WUHDWPHQW
,QDSULRUVWXG\ZLWKRYHUWKHFRXQWHU27&VWUHQJWKWRSLFDOF DSVDLFLQLQWKH
&*6YHKLFOH6WXG\9=8LWZDVQRWLFHGWKDWWKHSODFH ERHIIHFWIRUWKHYHKLFOH
FRQWUROLWVHOIUHVXOWHGLQVXEMHFWUHVSRQVHUDWHVRIWR RIVXEMHFWVDWWDLQLQJ!
SDLQVFRUHUHGXFWLRQRYHUWKHILUVWIRXUGD\VRIGDLO\RQFHDG D\DSSOLFDWLRQXVLQJWKH
PP9LVXDO$QDORJ6FDOH9$6IRUSDLQDVVHVVPHQW,QWKHV DPHVWXG\WZLFHGDLO\
DSSOLFDWLRQRI&*6YHKLFOHUHVXOWHGLQVXEMHFWUHVSRQVHUDW HVLH!SDLQVFRUH
UHGXFWLRQRIIURPWRRYHUWKHILUVWIRXUGD\VRIWUHDW PHQW7KHYHKLFOHFRQWURO
UHVSRQVHUDWHVLQ9=8DUHWDEXODWHGEHORZ
6WXG\
$UPKUVDIWHU
VW$SSOKUVDIWHU
QG$SSOKUVDIWHU
UG$SSOKUVDIWHU
WK$SSO
2QFH'DLO\    
7ZLFH'DLO\    

7KHPD[LPXPPHDQSODFHERUHVSRQVHUDWHDIWHUFRPSOHWLRQRIGD LO\WUHDWPHQWVRQFH
RUWZLFHGDLO\ZDVIRURQF HGDLO\DQGIRUWZLFH GDLO\
,QDQRWKHUSUHYLRXVVWXG\9=8&*6ZLWKFDSVDLFLQ ¬≥&*6¬¥
DQG&*6ZLWKFDSVDLFLQ¬≥ &*6¬¥ERWKSURYLGHGDY HU\KLJKUHVSRQVH
UDWHLHZLWK!UHGXFWLRQLQWKH1XPHULFDO5DW LQJ6FDOH156SDLQ
VFRUHDIWHUMXVWRQFHGDLO\DSSOLFDWLRQVPXFKKLJKHUWKDQW KHUHVSRQVHUDWHIRU
YHKLFOH LQ 6WXG\ 9=8 6WXG\ 9=8 ZDV QHLWKHU YHKLFOH R U SODFHER
FRQWUROOHG
+RZHYHULQ\HWDQRWKHUSUHYLRXVVWXG\9=8WKHUHVSRQVH UDWHIRUYHKLFOHZDV
HVVHQWLDOO\WKHVDPHDVIRU&*6LHUHGXFWL RQLQ156SDLQVFRUH
7KLVZDVDQXQH[SHFWHGRXWFRPH
%RWK9=8DQG9=8ZHUHFRQGXFWHGLQWKH'RPLQLFDQ5HSX EOLF¬≥'5¬¥
XQGHUDSSURYDOIURPWKHQDWLRQD ODXWKRULW\>&21$%,26@DQGWKH( WKLFV&RPPLWWHHRI
WKHFOLQLFDOVLWH,QFRQWUDVW9=8ZDVFRQGXFWHGLQWKH 86ZLWKORFDO,5%
DSSURYDO,WKDVEHHQVX JJHVWHGWR9L]XULWKDWVRFLDOQRUPVLQ WKH'RPLQLFDQ5HSXEOLF
DUHVXFKWKDWWKH\PD\PDUNHGO\DPSOLI\WKHPDJQLWXGHRIWKHSO DFHERUHVSRQVH,IRQH
DVVXPHVWKDWWKHYHKLFOHLWVHOIKDVQRDQDOJHVLFSURSHUWLHVWK HQWKHSODFHERUHVSRQVHLQ7KLVZDVDQXQH[ SHFWHGRXWFRPH
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 21 VZU00023 (in the DR) was approximately twice what was seen in VZU00022 (in the 
U.S.). 
This marked difference between the response to  placebo (vehicle), using the same 
vehicle, in the U.S. study compared to the  non-U.S. study, conducted in the Dominican 
Republic, appears to  be consistent with the  known higher rates of placebo  response in 
studies conducted in Latin American countries[5], and which effect is within the well -
known influence of cultural differences in placebo respons es [6]. The differences 
between placebo responses in the same studies conducted in Latin America and Europe 
and the corresponding differences for active treatment response are tabulated below 
(Table 1‚Äì1). The data in Table 1 suggest that on average, the placebo response in a 
study conducted in a Latin American culture country (such as the Dominican Republic) 
will be circa 2.6 times greater t han in the same study conducted in European countries. 
This, by extension, suggests that the placebo response in a Latin American study may 
be similarly higher compared to the same study conducted in the U.S., the U.S. culture 
being typically more European  than Latin American.  Per Figure 1‚Äì3 once daily 
application of vehicle reduced group mean OA pain score to 60% of baseline by Day 
28 in the U.S. OTC study whereas the  vehicle reduced group mean OA pain score to 
25% of baseline by Day 33 in the Dominican Republic study. Looking at these percent 
of baseline values in a different light, the absolute reduction  of OA pain score 
associated with vehicle treatment was 40% for the U.S. study and 75% for the 
Dominican Republic study. The ‚Äúabsolute reduction‚Äù is 100% less the percentage of 
baseline at the assessment time (i.e., the degree of pain relief associated with a 
treatment). So, the placebo (vehicle) effect in the Dominica n Republic study appears 
to be 1.9-times greater than the vehicle effect in the U.S. study. This is well within the 
range of differences reported by Xu et al. (2016).[5] 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 22 Table 1‚Äì1. Differences in Latin American and European Placebo Responses and 
Corresponding Latin American and European Responses to Active Treatment  
(Source: Study VZU00023)  
Study # LA Placebo  EU Placebo  LA/EU  LA Active  EU Active  LA/EU 
Study 1 61 28 2.18  38 45 0.84 
Study 2 66 37 1.78  56 46 1.22 
Study 3 58 35 1.66  51 55 0.93 
Study 6 68 23 2.96  57 57 1.00 
Study 9 42 13 3.23  60 52 1.15 
Study 10 53 15 3.53  75 50 1.50 
Average   2.56    1.11 
S.D.   0.79    0.24 
% SD   31%    21% 
Data from Figure 1 in Xu et al., Arthritis Rheumatol., 68(suppl 10), Abstract # 2594 (2016)[5] 
It can be seen, also, from Table 1‚Äì1 that the difference in active treatment response in 
Latin America conducted studies and European conducted studies is slight.  One can 
speculate that the large differences noted for placebo re sponses and the small 
differences noted for active treatment responses may be due to a cultural difference in 
the expectations of Latin American subjects compared European subjects. The Latin 
American may tend to believe more strongly that what the doctor or clinic is doing will 
help them, ergo the high placebo responses in Latin America; whereas, the European 
subjects may have lower expectations of obtaining relief, and a lower placebo response 
as a result. For active treatment, if the study treatment is a ctually beneficial, then the 
responses of European subjects and Latin American subjects would be similar, as is 
reported by Xu et al. (2016).[5] The role of cultural differences in expectations regarding 
treatment outcomes is well recognized and has been addressed by Bhugra and 
Ventriglio (2015).[6] 
In contrast to the magnitude of cultural effects on placebo response, the data presented 
by Xu et al. ( 2016) suggest t hat cultural differences in response to active treatment 
appear to be slight . [5] This suggests, in turn, that the pain relief efficacy data for active 
treatment (C GS-200-5) in study VZU00023 will hold up in the U.S. study planned 
under this protocol. Conversely, the large cultural differences in placebo responses, 
along with experience with vehicle response in a U.S. OTC product study, suggest that 
the vehicle response in the clinical study planned under this Investigational New Drug 
(IND) application will be much lower than was observed in study VZU00023 and likely 
similar to what was seen in the U. S. OTC product study.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 23 1.2 NONCLINICAL TOXICOLOGY SUMMARY  
Sponsor has conducted a number of non -clinical toxicology studies  with high strength 
Capsaicin topical liquid. These studies  have, for the most part, been conducted with a 
different formulation of high strength topical capsaicin  than that which will be 
investigated under Protocol VZU00025 . This alternate formulation is termed CGS -125 
and contains  additional OTC Monograph topical analgesic agents. Table 1‚Äì2 below 
shows the difference between CGS -125 with 5% Capsaicin and CGS -200-5.  
Table 1‚Äì2. Comparison of CGS -125-5 and CGS -200-5 Composition  
Component  CGS-125-5 CGS-200-5 
Capsaicin  5% 5% 
Distilled Water   44.55% 
Dehydrated Alcohol   20% 
Polysorbate 80   10% 
Diethylene Glycol Methyl Ether   10% 
Propylene Glycol   10% 
Na Hyaluronate SLMW (~20K Daltons)   0.30% 
Na Hyaluronate (~1,000K Daltons)   0.15% 
Methyl Salicylate  50%  
Menthol 15%  
Camphor 11%  
Phenol 1.50%  
Dehydrated Alcohol  17.5%  
 
The CGS -125 formulation contains a number of OTC Monograph topical analgesics. 
These are known to have pharmacological activity and present the potential that the 
CGS-125 formulation could have more potential for toxicities than CGS -200, which 
contains non e of these ingredients.  
Both formulations contain similar levels of dehydrated alcohol (i.e., ethanol), so they 
are comparable in this regard, CGS -200 has, otherwise, only one compound that has 
known pharmacological activity (capsaicin) and it is at the same level as in CGS -125-5. 
The excipients in CGS -200 are all of low toxicity potential.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 24 The non-clinical toxicity studies that have been conducted on CGS -125, which include 
one in which CGS -125 and CGS -200 were compared di rectly for tolerability on 
application to rats, are listed following with an outcome summary for each.  
Central Nervous System ( CNS) Safety Pharmacology  
A Functional Observation Battery (FOB) Neurological Assessment in the Male 
Sprague Dawley Rat Following a Single Dermal Application (Study # 1015 -2201 / 
CiTox Labs, Montreal, Canada)  
CGS-125 (at 5%, 10% and 20% Capsaicin) t ested at maximum practical 
dose. Single dermal application of 200 ¬µL volume over 50 cm2 area for 2 hrs 
then removal with PEG 300. No suggestion of neurological deficits or 
effects. 
Respiratory Safety Pharmacology  
A Respiratory Safety Pharmacology Study in Conscious Male Sprague Dawley Rat 
Following a Single Dermal Application (Study # 1015 -2211 / CiTox Labs, 
Montreal, Canada)  
CGS-125 (at 5%, 10% and 20% Capsaicin) tested at maximum practical 
dose. Single dermal application of 200 ¬µL volume over 50 cm2 area for 2 hrs 
then removal with PEG 300. No suggestion of respiratory deficits or effects.  
Cardio-Vascular Safety Pharmacology  
A Cardiova scular Function Safety Pharmacology Study in Conscious Telemetered 
Male Beagle Dog Following a Dermal Application (Study # 1015 -2292 / CiTox 
Labs, Montreal, Canada)  
CGS-125 (at 5%, 10% and 20% Capsaicin) tested at maximum practical 
dose. Single dermal appl ication of 200 ¬µL volume over 50 cm2 area for 2 hrs 
then removal with PEG 300. No suggestion of cardio -vascular deficits or 
effects. 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 25 Tolerability  on Application, Rabbit  
Dermal Tolerance of Topical Capsaicin Formulations in Rabbits (Study # 2007-
6987 / Charles River Laboratories, Horsham, PA)  
CGS-125 (at 5% and 20% Capsaicin) tested at maximum practical dose. 
Single dermal application of 800 ¬µL volume over 200 cm2 area for 2 hrs 
then removal with PEG 300. Vehicle, 5% and 20% well tolerated. N o 
suggestion of safety issues  observed.  
Tolerability  on Application, Dog  
A Single Dermal Application Pilot Tolerability Study in Beagle Dogs  
(Study # 2015 -2182 / Charles River Laboratories, Horsham, PA)  
CGS-125 (at 5%, 10% and 20% Capsaicin) tested at max imum practical 
dose. Single dermal application of 1600 ¬µL volume over 400 cm2 area for 
2 hrs then removal with PEG 300. Vehicle, 5%, 10% and 20% well 
tolerated. No suggestion of safety issues observed.  
Tolerability on Application, Rat  
Single Dose Dermal To lerance Study of Two Capsaicin Formulations  
(Study # 2007 -3449 / Charles River Laboratories, Horsham, PA)  
Capsaicin in CGS -125 (at 0% and 20% Capsaicin) and in CGS -200 (at 2%, 
5% and 10% Capsaicin) tested at maximum practical dose.   
Both formulation teste d at maximum practical dose. Single dermal 
application of 200 ¬µL volume over 50 cm2 area for 2 hrs then removal with 
PEG 300.  
CGS-125 Outcome : Vehicle and 20% well tolerated. No suggestion of 
safety issues observed.  
CGS-200 Outcome : Both 2% and 5% well to lerated. 10% elicited strong 
aversion reaction in rats. No suggestion of safety issues. ( Note: In non-U.S. 
clinical studies application of CGS -200-10% once daily for 1 hour on 4 
consecutive days has been well tolerated.)  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 26 Repeat Dose Toxicology in Rats  
A Seven Day Repeat Dose Dermal Toxicity Study of CGS -125 in Rats with a Four 
Week Recovery Period (Study # 2008 -0727 / Charles River Laboratories, Horsham, 
PA) 
CGS-125 (at 5%, 10% and 20% Capsaicin) tested at maximum practical 
dose. Seven (7) consecutive daily dermal applications of 200 ¬µL volume 
over 50 cm2 area for 2 hrs then removal with PEG 300. Vehicle, 5%, 10% 
and 20% well tolerated. No systemic or local to xicities elicited (on gross 
and histopathology examinations and assessment s, hematology, urinalysis, 
or blood chemistries) . No suggestion of safety issues.  
Repeat Dose Toxicology in Rabbits  
A Seven Day Repeat Dose Dermal Toxicity Study of CGS -125 in Rabbit s with a Four 
Week Recovery Period (Study # 2008 -0728 / Charles River Laboratories, Horsham, 
PA) 
CGS-125 (at 5%, 10% and 20% Capsaicin) tested at maximum practical 
dose. Seven (7) consecutive daily dermal applications of 800 ¬µL volume 
over 200 cm2 area for 2 hrs then removal with PEG 300. Vehicle, 5%, 10% 
and 20% well tolerated. No systemic or local toxicities elicited (on gross 
and histopathology examinations and assessments, hematology, urinalysis, 
or blood chemistries). No suggestion of safety issues.  
Mutagenicity  
Bacterial Reverse Mutation Assay (Study # AE58RS.502 -ICH.BTL / BioReliance, 
Rockville, MD)  
Capsaicin in CGS -125 tested in vitro against S. typhimurium TA98, TA100, 
TA1535, TA1537; E. coli WP2 uvrA at up to 5000 ¬µg/plate. No evidence 
of mutagenic  activity. 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 27 Clastogenic Potential  
In Vitro Mammalian Chromosomal Aberration Assay in CHO Cells  
(Study # AE58RS.331 -CH.BTL / BioReliance, Rockville, MD)  
Capsaicin in CGS -125 tested in vitro against Chinese Hamster Ovary cells 
(CHO) at up to 30 ¬µg/mL No evidence of clastogenic  activity 
1.3 PREVIOUS CLINICAL EXPERIENCE  
Study VZU00020  
This was a clinical study comparing the single dose tolerability of 5% and 10% 
capsaicin in CGS -125 and in CGS -200 (VZU00020) demonstrated that CGS -200 with 
5% and 10% capsaicin produced a mean burning - stinging pain (‚ÄúBSP‚Äù) score of not 
more than 2.5 on a  0 ‚Äì 10 NRS scale. In this same study the number of subjects 
reporting an NRS BSP score of 5 or greater (on the 0 ‚Äì 10 scale) is as tabulated in  
Table 1‚Äì3 below: 
Table 1‚Äì3. Number of Subjects  with BSP > 5 At Times After CGS -200-5 and 
CGS-200-10 Application in Study VZU00020  
% Caps 15 Min Post  30 Min Post  60 Min Post  90 Min Post  
5% 2/15 2/15 3/15 3/15 
10% 3/15 1/15 3/15 2/15 
 
Study VZU00021  
This was a study in which CGS -125 formulation of 5% and 10% capsaicin and CGS -
200 formulations of 5% and 10% were applied once daily for 1 hour on each of four 
sequential days to subjects with confirmed knee OA and a baseline NRS OA knee pain 
score of 5 or greater.  OA knee pain was assessed daily on Days 1 ( before the first 
application) and then on Days 2, 3 and 4 (prior to the daily application) and again on 
Days 5, 19 and 33. Burning -stinging pain at the applic ation site was evaluated on a 
0 ‚Äì 10 NRS scale. Erythema, scaling and pruritus were also assessed and scored at each 
protocol assessment time.  
In VZU00021, both CGS -200-05 and CGS -200-10 gave a high level of pain control 
with 85% or greater of subjects ex periencing a reduction from baseline NRS of 50% or 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 28 greater and this pain relief lasted for at least 29 days after the last application of the 
investigational drug product. The degree and duration of pain relief was similar for 
CGS-125-05 but appeared to be  less over the first 4 days for CGS -125-10: 
 
Drug Criterion:  
> 50% NRS 
Reduction  Day 1 
1st Appl. Day 2 
2nd Appl. Day 3 
3rd Appl. Day 4 
4th Appl. Day 5 Day 19 Day 33 
Percent on Subject Knees Meeting the Criterion  
CGS-200-05 0% 42% 85% 88% 100% 81% 92% 
CGS-200-10 0% 45% 97% 97% 100% 79% 86% 
CGS-125-05 0% 60% 80% 80% 90% 100% 100% 
CGS-125-10 0% 0% 57% 57% 100% 100% 100% 
 
Both formulations at either strength were well tolerated and reduced OAKP by 
75% or more compared to baseline. Analgesic effect persisted to Day 33 (last 
follow up day). No serious adverse events ( SAEs), no adverse events ( AEs) 
resulting in subject discontinuation or subject requested withdrawal, only AEs that 
were possibly, probably or definitely treatment related were: (a) local at the 
application site and Rheumatology Common Toxicity Criteria ( RCTC) toxicity 
grades were generally 1 (mild) and at highest 2 (moderate) and were mostly BSP 
with less frequent erythema, pruritus, and scaling (latter only for CGS -125-10); and 
(b) coughing / sneezing during or following application (RCTC Grade 1, mild) 
which was observed in a higher proportion of CGS -125 subjects (40% - 60%) than 
in CGS-200 subjects (20% - 27%). Comparison of Day 33 (study exit) values for 
serum chemistry and hematology with values at screening showed no remarkable 
changes in any subjects and no differences for any subject, comparing Day 33 to 
Screening, that were atypical of the normal variations in serum chemistry and 
hematology values in individuals for blood sampling at different time points. In 
summary, no suggestion of systemic toxicitie s related to treatment was observed.  
In Study VZU00021 neither vehicle or a true placebo was used as the study was 
designed to compare the CGS -200 formulation with the CGS -125 formulation in terms 
of tolerability and efficacy for a 4 -day, once daily for 1-hour treatment regimen.   
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 29 Study VZU00023  
This was a vehicle -controlled study of safety, tolerability and efficacy of CGS -200 
5% capsacian  in subjects with OA of the knee. Single daily application for four 
consecutive days with 93 days (13 weeks) follow up.  
CGS-200-5 was well tolerated and reduced OAKP at 13 weeks by 93% compared 
to baseline. No SAEs, no AEs resulting in subject discontinuation or subject 
requested withdrawal, only AEs that were possibly, probably or definitely 
treatment related were: (a) loc al at the application site and RCTC toxicity grades 
were generally 1 (mild) and at highest 2 (moderate) and were mostly BSP (in 100% 
of subjects) with less frequent erythema (72% of subjects), and pruritus (56% or 
subjects) ; and (b) coughing / sneezing du ring or following application (RCTC 
Grade 1, mild) which was observed in 20% of subjects. No suggestion of systemic 
toxicities related to treatment was observed.  
In this study, Vehicle control had an unexpectedly high placebo effect, with 
reduction of OAKP s cores by around 83% at 13 weeks. Unusually high placebo 
effects are known from  the literature to occur in studies in Latin American 
countries such as the Dominican Republic.[5] No SAEs, no AEs resulting on subject 
discontinuation or subject requested withdrawal, only AEs that were possibly, 
probably or definitely treatment related were: (a) local at the application site and 
RCTC toxicity grades were generally 1 (mild) and at highest 2 (moderate) and were 
mostly BSP (in 35% of subjects) with less frequent erythema (15% of subjects), 
and pruritus (31% or subjects) ; and (b) coughing / sneezing during or following 
application (RCTC  Grade 1, mild) which was observed in 3.8% of subjects. In this 
study, serum chemistries, hematology and urinalysis data were collected at 
screening but not at a later time point. However, as a reference point, no remarkable 
differences for serum chemistry  and hematology were observed between screening 
values and vales at one month after study start in Study VZU00021. It was, 
therefore, concluded that in Study VZU00023 no remarkable differences in serum 
chemistry and hematology values between screening and one to three months after 
study start would be observed. No suggestion of systemic toxicities related to 
treatment was observed in Study VZU00023.   
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 30 CGS-200 specific efficacy data fr om Study  VZU00023 are summarized in the 
following figures:  
Figure 1‚Äì1. Group Mean NRS Pain as Percent of Baseline  
 
Figure 1‚Äì2. Group Mean WOMAC Pain as Percent of Baseline  
 
 0%5%10%15%20%25%30%35%40%45%50%55%60%65%70%75%80%85%90%95%100%105%
05101520253035404550556065707580859095100% Reduction
Study DayVZU0023: Mean % NRS Pain Reduction to D93
Active
PLACEBO
0%10%20%30%40%50%60%70%80%90%100%
0 20 40 60 80 100WOMAC Pain Mean % of Baseline
Study DayWOMAC Pain Mean % of Day 1
WOMAC Pain - ACTIVE
WOMAC Pain PLACEBO
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 31 It can be noted that for the NRS pa in scores ( Figure 1‚Äì1) the difference between 
placebo (vehicle) response and active treatment response is less than the difference 
between placebo (vehicle) response and active treatment response as assessed by the 
Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) pain 
subscale. Additionally, the placebo (vehicle) response is higher than expected based on 
data from a U.S. clinical study of Sponsor‚Äôs OTC Tentative Final Monograph ( TFM) 
capsaicin product (0.025% capsaicin topical liquid).  The placebo response in that study 
was in the range of only a  60% reduction in OA knee pain scores relative to baseline 
(using a 100 mm VAS scale for pain assessment).  This is illustrated in  Figure 1‚Äì3, next 
page, which superimposes the U.S. vehicle response data onto the VZU00023 response 
data through Day 33.  In the U.S. OTC study the final assessment time was at Day 28 
and the vehicle was applied daily for 7 consecutive days either once daily or twice daily 
(with an application interval time of approximately 12 hrs). The vehicle re sponse data 
shown in Figure 1‚Äì3 are for the once daily application of vehicle so as to be comparable 
to the once daily application of vehicle in study VZU00023.  In the U.S. study, twice 
daily application of vehicle pr oduced an approximately 55% reduction of group mean 
pain score relative to baseline.  
Figure 1‚Äì3. U.S. Conducted OTC Study Vehicle (Placebo) Response 
Superimposed on Vehicle and CGS -200-5 responses in Dominic an 
Republic Conducted Study VZU00023  
 0%5%10%15%20%25%30%35%40%45%50%55%60%65%70%75%80%85%90%95%100%105%
0 5 10 15 20 25 30 35% Reduction
Study DayVZU0023: Mean % NRS Pain Reduction to D33
Active
PLACEBO
OTC Placebo
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 32 This marked difference between the response to  placebo (vehicle), using the same 
vehicle, in the U.S. study compared to the  non-U.S. study, conducted in the Dominican 
Republic, appears to  be consistent with the  known higher rates of placebo  response in 
studies conducted in Latin American c ountries [5], and which effect is within the well -
known influence of cultural differences in placebo responses .[6] The differenc es 
between placebo responses in the same studies conducted in Latin America and  Europe 
and the corresponding differences for active treatment response reported in Xu et al. 
(2016) suggest that on average, the placebo response in a study conducted in a Lati n 
American culture country (such as the Dominican Republic) will be circa 2.6 times 
greater than in the same study conducted in European countries.  [5] This, by extension, 
suggests that the placebo response in a Latin American study may be similarly higher 
compared to the same study conducted in the U.S., the U.S. culture being typically 
more European than Latin American.  Per Figure 1‚Äì3 once daily application of vehicle 
reduced group mean OA pain score to 60% of baseline by Day 28 in the U.S. OTC 
study whereas the vehicle reduced group mean OA pain score to 25% of baseline by 
Day 33 in the Dominican Republic study. Looking at t hese percent of baseline values 
in a different light, the absolute reduction  of OA pain score associated with vehicle 
treatment was 40% for the U.S. study and 75% for the Dominican Republic study. The 
‚Äúabsolute reduction‚Äù is 100% less the percentage of b aseline at the assessment time 
(i.e., the degree of pain relief associated with a treatment). So, the placebo (vehicle) 
effect in the Dominican Republic study appears to be 1.9 -times greater than the vehicle 
effect in the U.S. study. This is  well within the range of differences reported by Xu et 
al. (2016).[5] 
1.4 SUMMARY OF SAFETY DATA  
There have been three clinical trials conducted with CGS -200-5 and CGS -200-10 
(VZU00020, VZU00021 , and VZU00023). Thes e have been conducted in the 
Dominican Republic with regulatory approval by CONABIOS and the local IRBs 
(Ethics Committees) for the study centers.  With respect to the investigational drug 
product vehicle (CGS -200-0): One trial has been conducted in the Dom inican Republic 
(VZU00023) and one trial was conducted in the U.S. (VZU00022). The U.S. study was 
for Sponsor‚Äôs OTC TFM product that contains 0.25% capsaicin in CGS -200 vehicle. 
To date: 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 33 ‚Ä¢ No SAEs have occurred  
‚Ä¢ AE‚Äôs that are possibly, probably or definitely associated with study treatment 
have been limited to mild -moderate and expected reactions at the site of 
application and which will resolve within a few days of occurrence.  
‚Ä¢ No suggestion of systemic toxicities has been observed  
Hematology and serum chemist ries were assessed for subjects in Study VZU00021 at 
screening and then again at Day 33 (last study assessment day and planned exit day). 
These are not tabulated here as for very study subject there were no remarkable changes 
or differences which were outs ide what is typical for hematology and serum chemistry 
assessments taken on the same person but at different times.  
The amounts of capsaicin to be applied in this study and the likely systemic uptake of 
capsaicin by subjects in this study are quite small and further support that the topical 
applications of capsaicin to the subject‚Äôs knees in the planned study will be safe for the 
subjects. For the initial investigation planned under this IND capsaicin will be applied 
in two strengths: 1% capsaicin (CGS -200-1) and 5% capsaicin (CGS -200-5). Also, the 
vehicle will be applied as a placebo control. The ingredients in CGS -200-1 and 
CGS-200-5 are as indicted in the tables that follow . 
CGS-200 Formulations at 1% and 5% Capsaicin Content  
Ingredient  CGS-200-5         
% w/w CGS-200-1      
% w/w 
Capsaicin  5 1 
Dehydrated Alcohol  20 20 
Polysorbate 80  10 8 
Diethylene Glycol Methyl Ether  10 10 
Propylene Glycol  10 10 
Na Hyaluronate (~1,000K Daltons)  0.15 0.16 
Na Hyaluronate SLMW (~20K Daltons)  0.30 0.32 
Distilled Water  44.55 50.52 
Totals 100.00 100.00 
 
The amount of CGS -200 applied to the knee per applicatio n is an approximate 
maximum of 0.15 gram per knee. If two knees receive application , then the total amount 
of CGS-200 applied per application is approximately 0.30 gram and this is applied to 
an area of approximately 200 cm2 (ca. 100 cm2 per knee).  Note that both knees will 
receive study drug application but only one knee will be the study knee on which 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 34 assessments are performed. Using CGS-200-5 as the maximum capsaicin strength 
product for investigations under this IND, the amounts of each component applied per 
application are provided in the table below.  
Components Application Amounts for  
CGS-200 at 5% Capsaicin Content  
(knee(s) treated: 0.3 g CGS -200 Total)  
Ingredient CGS-200-5 % w/w Per Application  
Capsaicin 5 15 mg 
Dehydrated Alcohol  20 60 mg 
Polysorbate 80  10 30 mg 
Diethylene Glycol Methyl Ether  10 30 mg 
Propylene Glycol  10 30 mg 
Na Hyaluronate (~1,000K Daltons)  0.15 0.45 mg 
Na Hyaluronate SLMW (~20K Daltons)  0.30 0.90 mg 
Distilled Water  44.55 133.65 mg 
Totals 100.00 300.00 mg 
 
These are all trivially small amounts for each of the components by the topical route.  
For the capsaicin, the total maximum amount applied, 15 mg, would be a topical dosage 
of 0.21 mg/kg for a 70 kg person. As an application per cm2 of surface area it wou ld be 
0.075 mg/cm2.  
One can compare the above 0.075 mg/cm2 (75 ¬µg/cm2) with published data on 
capsaicin uptake from the 8% Qutenza patch (Babbar et al., 2009 [full copy in the 
Literature Appendix to Module 2]).[7] Babbar et al. (2009) report that areas of 
1,000 cm2 were treated with patches containing capsaicin at 640 ¬µg capsaicin/cm2. 
Treatment durat ion was generally for 60 minutes (same as intended for the protocol 
under this present IND) but in some cases, was for up to 90 minutes.  The total amount 
of capsaicin applied and the unit dosage rate (¬µg/cm2) reported by Babbar et al. (2009) 
and estimate f or the initial clinical investigation planned under this IND and the ratio 
for comparing the Babbar et al. (2009) values to those estimated for the planned 
investigation are presented in the table below.  
Dose Index  Babbar et al., 2009 Protocol VZU00025  Ratio: 
Babbar et al., 2009 / 
VZU00025  
mg Total 640 mg 15 mg 43 
¬µg/cm2 640 ¬µg/cm2 75 ¬µg/cm2 8.5 
mg/kg 9.1 mg/kg  0.21 mg/kg  43 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 35  
Babbar et al. (2009) reported that the lower limit of quantification ( LLOQ) for their 
serum capsaicin assay was 0.5 ng/mL, which can be considered a sensitive high-
performance liquid chromatography ( HPLC) method.[7] They also report that the 
percentage of subje cts that had serum levels below the LLOQ was, in four different 
studies, respectively: 89%, 99%, 99.5% , and 94%. The median serum C max for all 
subjects in all studies was reported to be circa 2 ng/mL with a time to maximum effect 
(Tmax) of circa 1.5 hrs and with serum levels dropping to below LLOQ for all subjects 
by 4 ‚Äì 5 hrs after patch removal.  
Given that the unit surface area application rate for capsaicin in Protocol VZU00025 
will be only about 12% of that used in the studies repor ted by Babbar et al., (2009) it 
suggests that there would be no subjects in Protocol VZU00025 who would have 
capsaicin serum levels above an LLOQ of 0.5 ng/mL.[7]  
In Non-Clinical studie s (summarized above), no suggestions of potential systemic or 
site of application toxicities have bee n reported.  
1.4.1 Possible Risks  
All safety data obtained in this trial will be carefully evaluated and used to inform the 
design of any future clinical trials.  The potential risks of study participation include 
those associated with exposure to capsaicin and possible allergic reactions to capsaicin 
or one of the other components of the investigational products.  Effects of topical 
exposure to capsaicin include er ythema, edema, papules, scaling, pruritus, stinging and 
burning pain.  These manifestations may also occur in unintended locations through 
transfer of the investigational products from the treatment area to other sites on the 
skin, mucous membranes, and ocu lar surfaces. Inhalation of fumes or aerosolization of 
the investigational products may cause irritation of airways with symptoms such as 
coughing.  A temporary rise in blood pressure (hypertension) or difficulty sleeping 
could occur if pain from stinging a nd burning is severe.  All subjects will receive a full 
explanation of potential risks and will sign an informed consent form prior to study 
participation.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 36 2.0 STUDY OBJECTIVES  
The objectives of the present study are the following:  
‚Ä¢ To develop pain relief dose -response data for OAKP, compared to Vehicle, for 
the following concentrations of Capsaicin in CGS -200 vehicle: 1% and 5% using 
the WOMAC pa in subscale (VAS formatted) as the primary pain index for relief 
of OAKP.   
‚Ä¢ To confirm, in a U.S. based po pulation, the high safety profile for CGS -200-5 
that was reported in Studies VZU00021 and VZU00023 in a Dominican Republic 
population.  
‚Ä¢ To develop data for relief of signs and symptoms of osteoarthritis using the 
WOMAC subscales for pain, stiffness and function and total WOMAC score.  
‚Ä¢ To develop OAKP relief data using the 100 mm VAS scale.  
2.1 PRIMARY ENDPOINTS  
The Primary Efficacy endpoint of this study will be to examine the extent of reduction 
in the WOMAC pain  score, relative to baseline, provided by once  daily, one -hour 
application of Vehicle (CGS-200-0), CGS-200-1 and CGS -200-5 at the following 
assessment times:  
Baseline: < 30 minutes prior to first daily application  
Day 35  31 Days (+/- 3 days) after fourth daily application  
and based thereon to determi ne whether the responses for treatm ent with CGS -200-0, 
CGS-200-1, and CGS-200-05 are significantly different from Vehicle and from each 
other at the primary endpoint t ime.  
The Primary Safety  Endpoints  will be: 
(1) The application  of the study drug does not produce skin reactions (erythema, 
scaling, pruritus, or other) to a degree that is clinically of concern. Scoring of 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 37 erythema and scaling at the application sites and of pruritus will be assessed per 
the scoring  systems in  Appendix F. 
(2) No SAE‚Äôs either possibly, probably or definitely associated with study 
treatments.  
(3) Safety labs (hematology, serum chemistry and urinalysis ) do not produce other 
than minimal ‚Äì mild toxicities (Grade 1 or Grade 2). Scoring of clinical, 
hematological and urinalysis out of range findings for toxicity grading will be 
per Appendix B. 
2.2 SECONDARY ENDPOINTS   
Secondary Efficacy endpoints  will be: 
(1) The extent  of reduction in the WOMAC pain score, relative to baseline, 
provided by once daily, one -hour application of Vehicle  (CGS-200-0), CGS-
200-1, and CGS-200-5 at the following assessment times:  
Baseline: < 30 minutes prior to first daily application  
Day 5  24 hrs (+/- 3) after last of the 4 daily applications  
Day 19  15 days (+/ - 3) after last of the 4 daily applications  
Day 64  60 days (+/ - 3) after the last of 4 daily applications  
Day 94  90 days (+/ - 3) after the last of 4 daily applications  
(2) Day 5, 19, 35, 64 , and 94 WOMAC scores on the stiffness and function 
subscales as well as total WOMAC score (including the WOMAC pai n score).  
Secondary Safety  endpoints will be:  
(1) The distribution by study arms of specific AEs (i.e.: local application site 
reactions), and other AEs (inclusive of findings for hematology, serum 
chemistry and urinalysis ).  
(2) Evaluate the amount of concomitant pain medications used overtime  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 38 Tolerability  endpoints (which are secondary in nature) will be:  
(1) The application of study drug does not produce burning -stinging pain (‚ÄúBSP‚Äù) 
at the application site to a degree that is not acceptable to the subject. BSP at 
the application site, this will be assessed using a 0 ‚Äì 10 NRS scale without 
guideposts. ‚ÄúAccepta bility‚Äù of BSP will be queried per subject at the end of 
each application period.  
(2) The application of the study drug does not produce pruritus during application 
or in the 24 hrs post -application to a degree that is not acceptable to the subject 
or, if bothersome to the subject, cannot be managed by application of ice or a 
cold pack or compress . 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 39 3.0 STUDY DESIGN  
3.1 OVERALL STUDY DESIGN  
This is a multi -center, randomized, double -blind clinical trial to examine the 
comparative effects on OAKP of CGS-200-1 (1% C apsaicin content) (N= 40), 
CGS-200-5 (5% Capsaicin content) (N= 40), and CGS-200 Vehicle  (no Capsaicin ) 
(N=40) in subjects with OA of the knees according to the 1986 ACR criteria. Assigned 
doses will be applied at the clinic for 60 minutes on each of four co nsecutive days.  
Subjects will be randomized to one of the three Arms in this study: CGS-200-1 or 
CGS-200-5 or CGS-200-0 (Vehicle). All subjects will receive 4 consecutive days of 
treatment and will then be followed up until the Day 94 visit. 
Subjects will receive the study arm appropriate treatment as a topical application over 
the frontal aspect of the knee(s)  once daily on four consecutive days. The applications 
will be at the clinic but by the subject wearing gloves  under supervision of clinic 
personnel. The application will be left in place for 60 minutes and then washed off at 
the clinic by clinic personnel.  The amount of Investigational Drug Product to be applied 
is estimated to be approximately 0.13 mL based on experience in prior studies. E ven 
though both knee(s) will receive application of study test materials, with regard to 
reduction in  WOMAC pain and  VAS pain score associated with study treatments, only 
one knee will be indicated as the ‚ÄúStudy Knee‚Äù. This will be the knee with the highe st  
WOMAC pain score at baseline. If both knees have equal WOMAC pain scores at 
baseline, then the right knee will be considered the ‚ÄúStudy Knee‚Äù with regard to 
WOMAC pain and VAS pain score reduction.  
Data will be collected from Day 1 through Day 5 and t hen again on Days 19, 35, 64, 
and 94 for  efficacy, tolerability, and safety measures.  The Investigators, all site staff 
and Clinical Research Organization (CRO) personnel (except the Medical Monitor 
providing safety oversight) directly involved in the stud y will remain blinded to the 
treatment assignment throughout the trial.   
3.2 DOSE LIMITING TOXICITY  
AEs and SAEs will be assessed according to the Rheumatology Common Toxicity 
Criteria (RCTC) v2.0[8] (Appendix B). 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 40 Dose limiting toxicity (DLT) stopping rules for the study drug are based mainly on 
Grade 2 events related to the study drug, with the following exceptions:  
1. Cutaneous CGS-200-1 (Capsaicin 1%  Topical Liquid) and CGS-200-5 (Capsaicin 
5% Topical Liquid)  have the potential for being associated with Grade 2 
administration site reactions such as erythema, pain and edema, and the DLT 
threshold has been set at Grade 3.  
2. The cut-point of Grade 3 to de fine a DLT and stop further administration of study 
drug was selected for the safety of subjects since the RCTC only require permanent 
discontinuation of drugs that attain a Grade 4.  
A DLT will be defined as any toxicity occurring within 14 days of treatme nt with the 
investigational product, and meeting the following criteria:  
‚Ä¢ > Grade 3 AE including:  
‚àí Allergic / Immunologic: immune reactions, rhinitis;  
‚àí Cardiac: hypertension, hypotension;  
‚àí Dermatologic: reaction at site of study drug administration;  
‚àí Neuropsychiatric: inability to concentrate, insomnia (in absence of pain), 
peripheral sensory neuropathy.  
‚Ä¢ Any other ‚â• Grade 2 AE (excluding AEs captured above and pre -existing OA -
related conditions) . 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 41 4.0 SELECTION AND WITHDRAWAL OF SUBJECTS  
4.1 INCLUSION/ EXCLUS ION CRITERIA:  
Subjects entering the study must meet all inclusion and exclusion criteria.  
4.1.1 Inclusion Criteria:  
The subject must meet all of the following:  
1. Able to comprehend the informed consent form (ICF) and provide Informed 
Consent, and capable of comply ing with all study procedures;  
2. Male or female, 35 years of age to 75 years;  
3. OA of the at least one knee  according to 1986 ACR Classification Criteria;  
4. OA of at least one knee  must be confirmed by tibiofemoral joint radiographs 
obtained within the past 6 mo nths; 
5. RF negative and ESR <40 mm/hr;  
6. Chronic knee pain in at least one knee for > 3 months;  
7. WOMAC pain score of > 250 (using VAS WOMAC format) at  screening , and 
at baseline , in at least one knee ; 
8. Knee pain score of > 5 on the NRS pain scale at screening , and at baseline , in at 
least one knee;  
9. Knee pain is not potentially due to acute trauma unrelated to OA (no acute 
traumatic knee injury in medical history);  
10. No burning -stinging pain, unrelated to subject‚Äôs knee pain, a t intended site of 
application;  
11. Knee pain must be greater than pain in any other part of subject‚Äôs body;  
12. ACR global functional status I, II, or III (excluding IV);  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 42 13. If female, subject must be past childbearing age or otherwise must test negative 
for pregnancy. Males and females must agree to use effective birth control for 
at least 30 days after last dose of study drug.  
4.1.2 Exclusion Criteria:  
The subject must not have any of the following:  
1. Spontaneously improving or rapidly deteriorating OA of the knee;  
2. Rheumatoid or psoriatic arthritis, or a form of arthritis (e.g. gout, pseudogout), 
Paget‚Äôs disease of bone, or any other disease affecting the joints that are 
inconsistent with a diagnosis of idiopathic OA;  
3. Use of topical, oral, or injectable steroids for 1 month prior to screening, or 
intraarticular -visco-supplementation within 3 months prior to screening;  
4. Used any capsaicin -containing product on or in the vicinity of the knee within 
4 weeks prior to screening;  
5. Used topically applied products (including em ollients or moisturizers) on or in 
the vicinity of the knees or shaved the knees within 2 days prior to the first 
application of study drug;  or an open wo und near the knee; cutaneous erythema 
or edema; any inflammatory skin lesions such as eczema or psoriasis; cutaneous 
infections; or any other compromise of the skin;  
6. A history of sensitivity to topical substances inclusive of OTC topical 
analgesics;  
7. Significant cardiovascular, renal, or other diseases or conditions, or laboratory 
or other test abnorm alities that, in the opinion of the Investigator, would 
contraindicate participation in the trial;  
8. Labile or poorly controlled hypertension ;  
9. A psychiatric disorder or significant anxiety or depression that could interfere 
with the subject‚Äôs compliance wit h study procedures or completion of the study;  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 43 10. Requires daytime use of medications or substances (alcohol, benzodiazepines, 
barbiturates, muscle relaxants, tranquilizers, hypnotics) that could diminish 
their cognitive ability to comply with study procedure s; 
11. A history of drug or alcohol abuse within one year prior to screening;  
12. Requires or anticipates any surgical procedure within 3 months prior to 
screening, has had surgery on the affected joint within 6 months prior to 
screening, has a prosthesis  in either knee, or would require surgery while 
participating in the trial;  
13. Pregnant or nursing;  
14. Treated with an investigational drug, device or therapy within 30 days prior to 
screening.  
15. Body mass index  greater than 45 kg/m2 
16. Skin on or near knee is  broken or damaged or if there is an open wound on or 
near the knee.  
4.2 REPLACEMENT OF SUBJECTS  
Subjects that do not receive 4 complete consecutive daily doses and/or drop out before 
completing the Day 3 5 visit may be replaced if the reason for dropping out is other than 
lack of drug product tolerability.  A dose will be considered complete when at least 80% 
has been delivered on any study drug administration day; dosing will be considered 
complete overall when a total of at least 80%, in the aggregate, has been delivered 
across all study treatment days. Subjects that drop out or who cannot be followed up 
from after the Day 5 visit until the Day 3 5 visit may be replaced.  Up to 10 subjects per 
arm may be repl aced. 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 44 5.0 STUDY TREATMENT  
5.1 CGS-200-1, CGS-200-5, AND CGS -200-0 (VEHICLE)  
5.1.1 Formulation  
CGS-200-1 and CGS -200-5 are topical analgesic liquid s intended for application to 
intact, non -irritated skin in adults with musculoskeletal pain, including pain of OA of 
the hands, wrists, elbows, or knees for the relief of pain, reduction of stiffness, and 
increased functional activity . 
CGS-200-1 is a multi -component formulation in which the active ingredient for the 
intended therapeutic effect is capsaicin at a level of 1% for this study.  
CGS-200-5 is a multi -component formulation in which the active ingredient for the 
intended therapeutic effect is capsaic in at a level of up to 5% for this study.   
CGS-200-0 (Vehicle) contains all of the ingre dients in CGS -200-1 and CGS -200-5 
except for capsaicin . 
The composition of study test materials is provided in the table below.  
Ingredient  CGS-200-5 
% w/w CGS-200-1 
% w/w CGS-200-0 
Vehicle 
% w/w 
Capsaicin  5 1 0 
Dehydrated Alcohol  20 20 22.5 
Polysorbate 80  10 8 7 
Diethylene Glycol Methyl Ether  10 10 10 
Propylene Glycol  10 10 10 
Na Hyaluronate (~1,000K Daltons)  0.15 0.16 0.17 
Na Hyaluronate SLMW (~20K Daltons)  0.30 0.32 0.33 
Distilled Water  44.55 50.52 50 
    Totals 100.00 100.00 100.00 
 
CGS-200-1, CGS-200-5, and CGS-200-0 Vehicle will be stored at room temperature 
(15 - 30ÔÇ∞C) in a limited access location, protected from excessive light and heat. 
Storage conditions must also comply with the site‚Äôs institutional procedures and all 
applicable regulatory requirements.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 45 Under clinic supervisions, e ach dose will be applied by the subject (who will be 
wearing gloves provided by the clinic)  to the knee(s) over a 10 x 10 cm area on Days 
1, 2, 3, and 4 and at each application, will be washed off by clinic personnel after 
60 minutes (¬± 5 min).  
5.1.2 Packaging, Labeling and Storage  
The vial label will contain the following information at a minimum:  
‚Ä¢ Blinded code  number 
‚Ä¢ Volume (single dose vial; fill volume is up to 0.35mL)  
‚Ä¢ Storage instructions  
‚Ä¢ Manufacture Date  
‚Ä¢ Investigational drug statement  
‚Ä¢ Name of manufacturer  
‚Ä¢ Name of sponsor  
Study drug inventory/accountability forms will be monitored during the study and 
reconciled by the study monitor at the end of the study.  All used and unused 
investigational study drug must be accounted for on a study drug accountability form 
provided to the investigator by the site monitor.  
5.1.3 Rationale for Dose Selection  
In a previous clinical investigation with CGS -200 5% and 10% capsaicin 
(Study VZU00021), both strengths gave essentially the same degree of pain relief and 
over essentially the same time course to maximum effect and lasting at least 29 days 
after cessation of t reatment. Both strengths were well tolerated. Based on this, the 
choice of CGS -200-05 as the high dose Arm in this study is seen as rational . For the 
low dose Arm, CGS -200-1 was selected on the basis of being a reduction of 5 -fold 
from the 5% dose, which d egree of reduction is likely to give a lower response than the 
5% dose based on modeling of analgesic responses from 7 days of QD and BID doses 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 46 of 0.25% capsaicin in CGS -200 observed in a clinical study of Sponsor‚Äôs marketed 
OTC Monograph capsaicin topical  product.  
5.1.4 Dosage and Administration  
The study medication is for external use only and will be administered at the clinic by 
the subject under the supervision of trained site personnel.  Wearing gloves, supplied 
by the clinic staff, a  single dose of the ass igned treatment will be topically applied to 
each knee on each of four dosing days.  Both knees will be treated for all subjects , if 
possible, however only one knee will be the study knee on which assessments are 
performed . The first application  of medicati on will be at Visit 2 on Day 1 (initiated at 
Time 0). Dosing on each of the three subsequent treatment days should be performed 
at the same time of day ¬±2 hours in relation to the start time of the initial dose on Day  1.  
With the knee relaxed, in a straig ht and horizontal position, treatment will begin by 
identifying a 10 cm by 10 cm area where the upper boundary is 1 cm above the patella, 
the center is aligned with the midline of the patella, and the line bisecting the 10 cm by 
10 cm square has 5 cm on ei ther side medially and laterally to the midline of the patella.  
Each application of the study medication will consist of a single pass of the roller ball 
over the knee so as to completely cover the designated treatment area.  The treatment 
will be applied c ontinuously beginning at the upper left corner of the square and 
moving the rollerball horizontally to the upper right corner and moving back and forth 
in a continuous pattern in a downward progression until the entire square is covered.  
This should result in moistening the skin providing a thin film of medication 
(approximately 0.13 mL [or 0.13 gram] of drug product applied to 100 cm2 of knee 
surface, which represents 1.3 mg of solution per cm2). Areas that were already 
moistened should not be recoat ed. The study medication should not be applied to a knee 
if the subject is still experiencing stinging, burning, pruritus, erythema, or scaling from 
a prior application to that knee.  In the case of a dose that is skipped, the subject should 
return as sched uled for their next visit at which time they may receive the next 
scheduled application of study medication if their symptoms have subsided.  The 
treatment period will not be extended beyond 4 days.  
During the application process, care must be taken not to contaminate the outside of 
the bottle, other body surfaces, or equipment or other surfaces in the room.  Any 
suspected contamination should be dealt with by washing off the formulation as soon 
as possible.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 47 The subject‚Äôs knees will remain uncovered for 60  minutes (up to 65 minutes)  after 
dosing to allow for assessments and proper absorption of the study medication.  The 
subject must avoid touching the knee area during this time.  The knees will then be 
cleansed by trained personnel according to specific proc edures designed to remove any 
remaining residual formulation from the surface of the skin.  After the area is cleansed, 
the subject may cover their knees, but should avoid doing so if possible.  It is 
recommended that the subject wear shorts or a skirt durin g the treatment period rather 
than long pants.  During the four days of treatment, subjects should also avoid exposing 
the knees to any form of heat (hot water, vigorous exercise, direct sunlight, etc.).  If a 
subject experiences intolerable pain or severe i rritation from the study medication, they 
may apply cold water, ice, or a cold pack or cold compress to their knee.  If the subject 
continues to have unbearable pain, they should contact the study site for help with pain 
management.  In the event of an aller gic reaction or medical emergency, the Medical 
Monitor must be contacted immediately.  
Treatment assignment for all subjects enrolled in this study will be double -blind; the 
subjects and all site personnel and CRO personnel (except for the medical monitor 
providing safety oversight) involved in this study will not know the treatment given to 
any subject.  Every effort should be made to maintain the study blind.   
Subjects will be monitored closely during and after application of treatment for any 
signs of acut e adverse reactions.  If an allergic reaction occurs, suggested guidelines are 
as follows:  
‚Ä¢ Grade 3 or higher adverse reaction:  
‚àí If treatment is ongoing, it must be immediately and permanently 
discontinued , the study drug should be washed off, and the subject  should 
be treated symptomatically as clinically indicated.  
‚àí The subject will be followed for safety as clinically indicated until the 
toxicity resolves, and in the opinion of the investigator, no further follow -
up regarding the toxicity is needed.  Complete  documentation of the event is 
required.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 48 ‚Ä¢ Grade 2 adverse reaction:  
‚àí If treatment is ongoing, it must be immediately interrupted and the subject 
should be treated symptomatically as clinically indicated.  
‚àí Once the subject has recovered to baseline and, if in  the opinion of the 
investigator the benefit/risk is favorable, consideration can be given to 
restarting the treatment the next day after pre -medicating with an 
H2-receptor antagonist and acetaminophen.  
‚Ä¢ Grade 1 adverse reaction:  
‚àí If treatment is ongoing, it  may continue, but the subject should continue to 
be monitored carefully to ensure that ongoing signs and symptoms do not 
progress and worsen warranting intervention as described above.  
5.1.5 Reporting Product Defects 
Any defects with the investigational product s must be reported immediately  by the site 
to the Medical Monitor and Vizuri Health Sciences with further notification to the site 
monitor.  
5.2 CONCURRENT MEDICATIONS  
5.2.1 Allowed Regimens  
Subjects may continue their baseline medication(s) as long as the medications are not 
prohibited as outlined in Section 5.2.2. If for any reason de emed necessary by the 
investigator, a subject requires additional medication(s) or change of dose, the 
medication(s), dosage change, route of administration, start and stop dates, and the 
indication for which it was given must be recorded in the source doc uments and 
electronic case report form (eCRF).  
5.2.2 Prohibited Medications  
Subjects should not receive any of the following medications through Day 94 and for 
the additional times specified below:  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 49 ‚Ä¢ Topical, oral or injectable steroids for 1 month prior to scr eening, or 
intra-articular-visco-supplementation within 3 months prior to screening;  
‚Ä¢ Any capsaicin -containing product on or in the vicinity of the knee within 4 weeks 
prior to screening;  
‚Ä¢ Topically applied products (including emollients or moisturizers) on or in the 
vicinity of the knees within 2 days prior to the first applicati on of study drug ; 
‚Ä¢ Topical or any other therapy on the knees that, in the Investigator‚Äôs opinion, might 
affect the study evaluation of signs/symptoms;  
‚Ä¢ Daytime use of medications or su bstances (alcohol, benzodiazepines, 
barbiturates, muscle relaxants, tranquilizers, hypnotics) that could diminish 
cognitive ability to comply with study procedures;  
‚Ä¢ Investigational drug, device or therapy within 30 days prior to screening.  
5.3 PROHIBITED PROCEDURES  
Subjects should not undergo any of the following procedures through Day 94 and for 
the additional times specified below:  
‚Ä¢ Anticipates any surgical procedure within 3 months of screening;  
‚Ä¢ Had surgery on the affected joint within 6 months prior to screening;  
‚Ä¢ Prosthesis at the index joint.  
‚Ä¢ Subjects should not shave their knees within 2 days before Day 1 and through 
Day 5. 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 50 6.0 STUDY PROCEDURES  
6.1 SCREENING VISIT  
Written informed consent must be obtained before any screening procedu res are 
performed that are not considered part of normal patient care.  Screening for many 
subjects will be completed in 2 visits.  During the first visit, all screening activities with 
the exception of obtaining laboratory work should be completed. Prior  to this  second 
visit in which laboratory work will be collected, s ubjects must begin fasting (except 
water) for chemistry assessment beginning at midnight prior to the blood draw visit . If 
a subject presents for the first screening visit and has fasted on  his/her own since 
midnight the blood draw may be taken at the first screening visit and a second screening 
visit will not be required.  Table 6‚Äì1 shows all the procedures to be conducted at the 
Screening Visit.  Subjects should plan to be in the clinic a minimum 1.5 hours (up to  2 
to 3 hours ) each visit.  
Table 6‚Äì1 Screening Procedures  
Assessment  Within 28 days of Study Day 1  
Clinic Visit  X 
Informed Consent  X 
Inclusion / Exclusion  X 
Demographics  X 
Medical & Medication History  X 
Physical Exam  X 
Heights & Weight  X 
Vital Signsa X 
Knee X-raysb X 
12-lead electrocardiogram (ECG)c X 
Clinical Lab oratory Testsd X 
Serum Pregnancy or Follicle-stimulating hormone ( FSH) Teste X 
Application Site Pain, Erythema, Edema, Scaling, Pruritus Assessmentf X 
Exploratory Assessment of OA Knee Paing X 
WOMAC  X 
Assessment of Concomitant Medicationsh X 
a Vital signs include temperature, blood pressure, heart rate and respiratory rate.  
b Knee-X-rays of both knees must be obtained unless films/images performed within 6 months before screening. Copies of 
film and results will be requested.  
c Standalone 12 -lead ECG.  
d Clinical Laboratory Tests ( Appendix A): 
 Hematology : complete blood count (CBC) including red blood cells (RBC), hemoglobin, he matocrit, MCV, MCH, MCHC, 
white blood cells (WBC), differential white cell count, platelet count.  
ESR 
Chemistry : Blood Urea Nitrogen (BUN), creatinine, uric acid, bilirubin (total), sodium, potassium, calcium, magnesium, 
phosphorous (inorganic), chloride, bicarbonate, alkaline phosphatase (ALK), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), lactate dehydrogenase (LDH), gamma -glutamyl transpeptidase (GGT), creatine phosphokinase 
(CPK), albumin, total protein, and glucose  
Immunoglobulin M (IgM) RF  
Urinalysis : pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, specific gravity, leucocytes . Clinically significant 
abnormal dipstick results will require microscopic analysis.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 51 e Serum pregnancy test for premenopausal women; FSH test to confirm postmenopausal status (females only) for up to 
2 years after cessation of menses  
f Application site pain will be assessed on the NRS (0 -10); application site erythema/edema will be assessed using modified 
categorical Draize test (0 -3).[9] Scaling and pruritus will also be scored on a similar categorical scale (0 -3). Scoring for 
application site pain (not related to knee pain) and for erythem a, edema, scaling and pruritus. ( Appendix F and G). 
g Exploratory assessment of OA knee pain (average daily pain and daily worst pain) ( Appendix F).  
h Document all medications taken within 90 days of the Screening visit.  
 
6.2 ON-TREATMENT EVALUATIONS:  
Table 6‚Äì2 shows all procedures to be conducted during Study Days 1 to 4 when study 
drug is applied in the Clinic.  
Table 6‚Äì2 On Treatment Evaluations  
Assessment  Treatment Days  
TIMEFRAME  1 2 3 4 
Clinic Visit  X X X X 
Randomization  X    
Vital Signsa X X X X 
Urine Pregnancy Testb X    
Application Site Pain, Erythema, Edema, Scaling, Pruritus Assessmentc X X X X 
VAS OA Knee Pain Assessmentd X X X X 
WOMACe X    
Exploratory Assessment of OA Knee Painf X    
Drug Administration X X X X 
Assessment of Concomitant Medications  X X X X 
AE Assessments  X X X X 
a Vital signs include temperature, blood pressure, heart rate and respiratory rate pre -dose on Days 1 -4 and at 90 minutes (¬± 5 
min) after applying study drug to knees. 
b Urine pregnancy test at baseline on Day 1 for premenopausal women.  
c Application site pain will be assessed on NRS (0 -10); application site erythema/edema will be assessed using modified 
categorical Draize test (0 -3). Scaling and pruritus will also be scored on a similar categorical scale (0 -3). Scoring for 
application site pain (not related to knee pain) will be performed on drug administration Days 1 -4 (pre-application 
[ÔÇ£30 min], and at 15 (¬± 5 min), 30 (¬± 5 min), 60 (¬± 5 min) and 90 minutes (¬±  5 min) after application) and on Days 5, 20, 
and 35. Application site skin reactions (erythema, edema, scaling, pruritus) will be asses sed on drug administration Days  1-4 
(pre-application [ÔÇ£ 30 min], and at 15 (¬±  5 min), 30 (¬± 5 min), 60 (¬± 5 mi n) and 90 minutes (¬± 5 min) after application). (  
Appendix E and Appendix F). 
d OA knee pain to be scored on 100mm VAS scale pre -treatment (ÔÇ£ 30 min) on Days 1 -4. 
e WOMAC Pain, Stiffness, and Physical Function will be performed on Day 1 prior to drug administration (ÔÇ£ 30 min). 
f  Exploratory assessment of OA knee pain (average daily pain and daily worst pain) (pre-application [ <30 min]) (Appendix 
F). 
 
‚ÄúBASELINE‚Äù is defined in t his study as the WOMAC scores (pain, stiffness, function) and the 
VAS OA knee pain score recorded within 30 minutes of the first application of study drug.  
 
 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 52 6.3 FOLLOW -UP PERIOD EVALUATIONS  
Table 6‚Äì3 shows all procedures to be conducted during the Follow -up Period (Clinic 
Days 5, 19, 35, 64 and 94).  
Table 6‚Äì3 Follow-up Period Evaluations  
Assessment  Follow-up Period Days  
TIMEFRAME  5 
(24hrs post 
Day 4 [ÔÇ±4 
hrs]) 19¬±3 
(Post-
Treat 
Wk 3) 35¬±3 
(Post-
Treat 
Wk 5) 64 (+ 3), 
(Post-Treat 
Wk 9) 94 (+ 3) 
(Post-Treat 
Wk 13) Unscheduled,  
Early 
Termination,  
SAEe 
Clinic Visit  X X X X X X 
Vital Signsa X    X X 
Physical Exam       X 
Clinical Laboratory Tests  X  X  X X 
Application Site Pain, Erythema, 
Edema, Scaling, Pruritus 
Assessmentb X X X X X X 
VAS OA Knee Painc X X X X X X 
WOMACd X X X X X X 
Assessment of Concomitant 
Medications  X X X X X X 
AE Assessments  X X X X X X 
Study Exit      X  
a Vital signs include temperature, blood pressure, heart rate and respiratory rate.  
b Application site pain will be assessed on NRS (0 -10); application site erythema/edema will be assessed using modified 
categorical Draize test (0 -3). Scaling and pruritus will also be s cored on a similar categorical scale (0 -3). Scoring for 
application site pain (not related to knee pain) will be performed on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/ - 3 days), 
35 (+/- 3 days), 64 (+/ - 3 days) and 94 (+/ - 3 days). Application site skin reaction s (erythema, edema, scaling, pruritus) will 
be assessed on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/ - 3 days), 35 (+/ - 3 days), 64 (+/ - 3 days) and 94 (+/ - 3 days). 
(Appendix E and Appendix F). 
c VAS OA knee pain will be performed on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/ - 3 days), 35 (+/ - 3 days), 64 (+/ - 3 days) and 94 
(+/- 3 days).  
d WOMAC Pain, Stiffness, and Physical Function w ill be performed on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/ - 3 days), 35 (+/- 3 
days), 64 (+/ - 3 days) and 94 (+/ - 3 days). 
e Refer to Section 6.5 for assessments to be completed at time of SAE, early termination or unscheduled visit.  
 
 
6.4 BIRTH CONTROL REQUIREMENTS  
Female subjects of childbearing potential must agree to use a highly effective method 
of birth control (defined as those, alone or in combination, which result in a low 
failure rate, i.e., less than 1 percent per year, when used consistently and correctly)  
for at least 30 days after last dose of study drug . 
Male subjects must agree to use a highly effective method of birth control (defined as 
those, alone or in combination, which result in a low failure rate, i.e., less than 
1 percent per year, when used consistently and correctly) for at least 30 days after 
last dose of study drug . 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 53 The acceptable methods of birth control are:  
‚Ä¢ Implanted, injected, or oral contraceptives  
‚Ä¢ Intrauterine devices  
‚Ä¢ Barrier methods (male condom, female c ondom, diaphragm)  
‚Ä¢ Sexual abstinence (when this is the preferred and usual lifestyle of the subject)  
‚Ä¢ Male subjects who have had a vasectomy  
‚Ä¢ Female subjects who have had a hysterectomy, tubal ligation, or bilateral 
salpingectomy or women of postmenopausal st atus 
In addition, male subjects must not donate sperm during the study and for 30 days after 
the last dose of study drug.  
6.5 ASSESSMENTS AT TIME OF SAE, EARLY TERMINATION OR 
UNSCHEDULED VISIT  
Additional activities may be performed at the Investigator‚Äôs discr etion at the onset of 
an SAE, when subjects are prematurely taken off study, and/or for an unscheduled visit.  
‚Ä¢ Assess vital signs (BP, HR, RR, and T)  
‚Ä¢ Perform abbreviated symptom -driven physical exam (PE)  
‚Ä¢ Application site pain will be assessed on numerical p ain rating scale (0 -10); 
application site edema will be assessed using categorical Draize test (0 -3). 
Scoring for application site pain (not related to knee pain) and for erythema and 
edema will be performed at Early Termination and at Unscheduled Visits.  
‚Ä¢ VAS OA knee pain and WOMAC will be performed at Early Termination and at 
Unscheduled Visits.  
‚Ä¢ Collect blood:  
For local laboratory analysis:  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 54 ‚àí CBC with automated differential and platelets, and serum chemistry  
‚Ä¢ Document AEs and concomitant medications  
6.6 STUDY BLOOD DRAW VOLUME  
The total blood volume to be collected during the study is approximately 60 ml (two 
ounces). 
6.7 RECOMMENDATIONS FOR MANAGEMENT OF POTENTIAL 
TOXICITIES  
6.7.1 Allergic Reaction , Burning, or Pruritus  
In the case of any life -threatening event oc curring during the treatment, the study drug 
must be immediately and permanently discontinued.  While corticosteroids are strongly 
discouraged, they may be used if they are necessary for the safety of the subject.  
‚Ä¢ Rash/pruritus/urticaria  
‚àí If subject develops rash, pruritus, or urticaria, interrupt treatment if it is 
ongoing and promptly assess subject for any other associated 
signs/symptoms (e.g., hypotension, fever, respiratory distress).  
‚Ä¢ Consider treating with H2 receptor antagonists as clinically i ndicated. 
If rash / pruritus / urticaria is isolated and resolves either 
spontaneously or with intervention, treatment with the study drug may 
be restarted.   
6.8 CONCOMITANT MEDICATIONS/RESCUE MEDICATIONS  
Subjects may continue their baseline medication(s) as l ong as the medications are not 
among the prohibited medications listed in Section  5.2.2. The daily dose of each 
medication should be maintained thr oughout the study  since any changes to this 
background regimen may have an effect on the assessment.  Subjects are allowed to 
increase dosage of NSAIDs or use analgesics to treat minor pain throughout the study, 
provided all concomitant medications are back  to baseline dosages within 24 hours of 
a clinical assessment visit.   
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 55 If for any reason deemed necessary by the investigator, such as in the event of a 
substantial disease flare which cannot be treated with increased drugs (NSAIDs) or 
narcotic, a rescue me dication can be initiated at any time that is in the best interests of 
the subject.  Rescue medication should be carefully considered by the principal 
investigator ( PI) since there may be an effect on the results of the study.  All changes 
and start and stop  dates, and the indication for which it was given must be recorded in 
the source documents and eCRF.  Routine changes (dose, route, etc.) to the background 
treatments should not be performed.  
6.9 STOPPING CRITERIA  
6.9.1 Criteria for Adverse Event Assessment  
All AEs w ill be graded according to the RCTC v.2.0 ( Appendix B). Please refer to 
Section 8.0, Safety Assessments  for additional information . 
6.9.2 General Criteria for Stopping Study Drug  
The study drug will be permanently discontinued for an y subject who meets a DLT 
criterion as outlined in Section 3.2.  
6.9.3 Stopping Criteria  
Any ‚â• Grade 3 event considered related to the study drug and occu rring during 
administration of the study drug will result in its permanent discontinuation for that 
subject. The Medical Monitor  should be notified immediately and the subject should 
be followed for safety as clinically indicated until the toxicity resolve s and in the 
opinion of the investigator, no further follow -up regarding the toxicity is needed.  
6.10 WITHDRAWAL OF SUBJECTS FROM STUDY  
Subjects will be free to withdraw from treatment or from the study at any time for any 
reason, or they may be withdrawn/remov ed, if necessary (see reasons for withdrawal 
below). It is understood by all concerned that an excessive rate of withdrawals can 
render the study uninterpretable; therefore, unnecessary withdrawal of subjects should 
be avoided.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 56 Subjects will be removed fro m treatment for the following reasons:  
‚Ä¢ Unacceptable acute toxicities defined as:  
‚àí Occurrence of a DLT  
Subjects will be removed from the study for the following reasons:  
‚Ä¢ Withdrawal of consent  
‚Ä¢ Non-compliance/Lost to follow -up 
‚Ä¢ Pregnancy  
If treatment with study drug is interrupted and permanently stopped, subjects should 
remain on study and will be followed for scheduled safety and study assessments 
through Day 3 5. If the subject goes onto other treatment, this should be noted in the 
source documents and th e concomitant medications eCRF.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 57 7.0 CLINICAL ACTIVITY  
Evidence of clinical activity will be assessed by the VAS OA knee pain scores recorded 
at pre-dose (< 30 min) on Days 1 2, 3, 4, and on Days  5, 19, 35, 64 , and 94.  
The WOMAC instrument will we be used to evaluate the effectiveness of CGS -200-1 
and CGS -200-5 in the management of signs and symptoms of OA of the knee in 
addition to just management of OA knee pain on Days 5, 19, 35, 64 , and 94. 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 58 8.0 SAFETY ASSESSMENTS  
8.1 ADVERSE EVENTS  
8.1.1 Definitions  
The AE mon itoring period begins with the start of study drug administration on Day 1 
and continues through Day 94. 
ADVERSE EVENT EXPERIENCE (AE) ‚Äì any unfavorable or unintended sign, 
symptom, or disease that is temporally associated with the use of an investigationa l 
drug but is not necessarily caused by the investigational drug.  This includes worsening 
(e.g.; increase in frequency or severity) of pre -existing conditions.  
SERIOUS ADVERSE EVENT (SAE) ‚Äì an AE resulting in any of the following 
outcomes:  
‚Ä¢ Death 
‚Ä¢ Life-threatening (immediate  risk of death)  
‚Ä¢ Inpatient hospitalization  
‚Ä¢ Prolongation of existing hospitalization  
‚Ä¢ Persistent or significant disability or incapacity  
‚Ä¢ Congenital anomaly/birth defect  
‚Ä¢ Medically important*  
*Important medical events that may not result in dea th, be life -threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical 
judgment, may jeopardize the subject and may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition.  Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias or convulsions that do not result in a subject‚Äôs 
hospitalization, or the development of drug dependency or drug ab use. 
UNEXPECTED ADVERSE EVENT ‚Äì any adverse event, the specificity or severity of 
which is not consistent with the current Investigator Brochure (IB).  Expected means 
that the event has previously been observed with the study drug and is identified and/or 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 59 described in the current IB.  It does not mean that the event is expected with the 
underlying disease(s) or concomitant medications.  
8.1.2 Reporting to the Sponsor  
All AEs that are identified from the start of study drug  administration and throu gh 
Day 94 will be documented in the source documents and the AE eCRF.  All data fields 
on the AE eCRF should be completed.  
SAE must also be documented on the SAE Worksheet and sent to the sponsor/designee 
within 24 hours of site personnel becoming aware of an SAE.  The SAE Worksheet 
should be completed as much as possible but should not be held until all information is 
available.  Additional information, follow -up information, and corrections should be 
provided on subsequent SAE Worksheets that are cl early identified as follow -up (#1, 
#2, etc.) reports.  SAE Worksheets should be sent by Email with Telephone Notification 
to the Drug Safety Department at:  
  Telephone #:  1-513-619-4771 
  Email:  CTIsafety@CTIfacts.com    
Drug Safety personnel will be availa ble to answer questions and assist site personnel 
in documenting SAEs and completing the SAE worksheet.  
8.1.3 Investigator Evaluation of Adverse Events  
The determination of seriousness, severity and causality must be made by the physician 
investigator  who is qua lified to review AE information, provide a medical evaluation 
of AEs, and classify AEs based upon medical judgment.  The investigator will evaluate 
all AEs with respect to seriousness (criteria listed above), severity, and causality 
(relationship to study d rug) according to the guidelines listed below.   
Severity will be graded using the RCTC, v2.0.  The RCTC is provided in Appendix B. 
In the event that an  AE does not have a RCTC code, the following severity 
classifications will be used:  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 60 SEVERITY  
Grade 1: Mild    Causing no limitation of usual activities  
Grade 2: Moderate   Causing some limitation of usual activities  
Grade 3: Severe   Causing inability to carr y out usual activities  
Grade 4: Life Threatening*  Potentially life threatening or disabling  
* Note ‚Äì a severity assessment of Life Threatening is not necessarily the same as Life 
Threatening as a ‚ÄúSerious‚Äù criteria.  The latter means that the event is an im mediate 
threat to life as opposed to a potential threat to life.  
8.1.3.1 Assessment of Seriousness  
Event seriousness will be determined according to the protoc ol definition of SAE in 
Section 8.1.1. 
8.1.3.2 Assessment of Severity  
Event severity will be assigned according to the RCTC, v2.0.  
8.1.3.3 Assessment of Causality  
The investigator is required to provide an assessment of causality or relationship  of 
AEs to the study drug based on 1) temporal relationship of the event to the 
administration of study drug; 2) whether an alternative etiology has been identified; 
and 3) biological plausibility.  The causality assessment categories that will be used for 
this study are described below.  
Note: If a causality assessment is not provided, a possible relationship will be assumed 
for regulatory reporting purposes.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 61 Causality assessments that are considered Not Related  to study drug:  
None: The event is related to an etiology other than the study drug (the alternative 
etiology must be documented in the subject‚Äôs medical record).  
Unlikely: A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which mak es a causal relationship 
improbable, and in which other drugs, chemicals or underlying disease 
provide plausible explanations.  The event is unlikely to be related to the 
study drug and likely to be related to factors other than study drug.  
Causality assess ments that are considered Related to study drug:  
Possible: A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administrations of the drug, but which could also be 
explained by concurrent disease or other drugs or ch emicals. Information 
on drug withdrawal may be lacking or unclear.  
Probable:  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, unlikely to be attributed to 
concurrent disease or other dr ugs or chemicals, and which follows a 
clinically reasonable response on withdrawal (dechallenge).  Rechallenge 
information is not required to fulfill this definition.  
Definite: A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administration, and which cannot be 
explained by concurrent disease or other drugs or chemicals.  The response 
to withdrawal of the drug (dechallenge) should be clinically plausible.  The 
event must be definitive pharmacologically  or phenomenologically, using a 
satisfactory rechallenge procedure if necessary.  
Note ‚Äì ICH guidelines (3/95) clarify ‚Äúreasonable causal relationship‚Äù to mean, 
‚Äúthat there are facts (evidence) or arguments to suggest a causal relationship.‚Äù  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 62 8.1.4 Follow-up of Adverse Events  
Adverse events will be captured from start of study drug treatment through Day 94. 
AEs are followed until final outcome is known or until the end of the study Day 94. 
AEs that are not resolved as of Day 94 are recorded on the AE  eCRF as ongoing and 
in the outcome field as Not Recovered/Not Resolved.  
SAEs that have not resolved by Day 94 are followed until final outcome is known.  If it 
is not possible to obtain a final outcome for a SAE (e.g., the subject is lost to follow -up), 
the reason a final outcome could not be obtained will be documented by the 
investigator.  
Pregnancy:  
All reports of pregnancy, or partner pregnancy, occurring after treatment with study 
drug and up to Day 94 must be reported via the Pregnancy Report form to S afety as per 
Section 8.1.2. Pregnancy itself is not an AE or SAE.  However, any events arising 
during the pregnancy will be assessed and reported acc ordingly as an AE or SAE.  A 
spontaneous abortion is always considered to be an SAE and shall be reported on the 
SAE Worksheet.  Furthermore, any SAE occurring as a result of a post -study pregnancy 
and considered reasonably related to the investigational pro duct by the investigator will 
be reported to Safety.  All reported pregnancy cases will be followed up until outcome.  
8.1.5 Post Study SAEs  
SAEs that occur after the Day 94 visit that are assessed by the investigator to be 
possibly, probably, or definitely relate d to study drug must be reported to Safety on a 
SAE Worksheet, as described in Section 8.1.2. Post study SAEs will not be documented 
on the AE eCRF.  
8.1.6 Reporting to the Institutional Review Board/Independent Ethics Committee  
All SAEs that are considered unexpected and related to the investigational drug will be 
reported by Vizuri Health Sciences/designee as 15 -Day (Expedited) reports to the 
regulatory au thority AND to all participating investigators.  Each investigator must 
notify the IRB/IEC responsible for reviewing the study at their site of all 15 -Day 
Reports. Expected and unrelated SAEs will be reported periodically.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 63 8.2 LABORATORY TESTS  
Clinical laborato ry tests (Appendix A) will be performed at Screening to determine 
eligibility and on Days 5 and 94 as outlined in  Section 6.0. 
All female subjects who are biologically capable of having children will have a serum 
pregnancy test at screening and urine pregnancy test prior to dosing on Day 1.  The 
results of the pregnancy tests must be confirmed to be negative before administ ration 
of study drug.  FSH testing will be performed on postmenopausal women for up to 
2 years after cessation of menses to confirm postmenopausal status.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 64 9.0 DATA ANALYSIS METHODS  
9.1 DETERMINATION OF SAMPLE SIZE  
A sample size analysis has  been performed  and suggests that a sample size of 
40 evaluable subjects per each of the three study arms will appropriately power this 
study.  
9.2 RANDOMIZATION AND BLINDING  
Treatment assignment for all subjects enrolled in this study will be double -blind; the 
subjects and all site personnel and CRO personnel (with the exception of the Medical 
Monitor providing safety oversight) involved in this study will not know the treatment 
given to any subject.  Every effort should be made to maintain the study blind.   
9.3 ANALYSIS  SETS 
The following three analysis sets will be defined for this study:  
The intent -to-treat (ITT) set will be defined as all randomized subjects, whether or not 
they receive study drug.   
The modified ITT (mITT) set will be defined as the subset of the ITT  subjects that 
receive at least one dose of study medication and have at least one evaluable 
post-dosing efficacy endpoint.  The mITT set will be defined based on randomized 
treatment rather than treatment actually received.  All efficacy analyses will be carried 
out using the mITT set.  
The safety (SAF) set will be based on the ITT subjects, but will be based on the 
treatment actually received rather than randomized treatment.  All safety analyses will 
be carried out using the SAF set.  
9.4 SUBJECT ACCOUNTABILITY  
All subjects who meet the inclusion criteria for the study, sign the informed consent 
form, and are enrolled and exposed to the study medication will be accounted for in the 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 65 analyses. Subjects who are deemed ‚Äò screen failures‚Äô  will not be accounted for in the 
data presentation of response or safety.   
9.5 STATISTICAL METHODS  
9.5.1 Analysis of Demographic and Subject Characteristics  
Subject demographic characteristics including age, gender, race, weight, and height 
will be summarized by treatment group.  Subject baselin e disease characteristics that 
are relevant to the evaluation of the treatment will be summarized by treatment group.  
9.5.2 Treatment Administration/Compliance  
The Investigators will be responsible for the storage, dispensing, inventory, and 
accountability of al l clinical supplies.  An accurate, timely record of the disposition of 
all clinical supplies must be maintained.  Subjects may be withdrawn from the study by 
the Sponsor for non -compliance with the protocol.   
9.5.3 Efficacy Analyses  
Primary Efficacy Endpoint  
The group mean LMS difference between each Active Treatment Arm and the Vehicle 
Arm for the WOMAC pain score at Day 35 will be tested for significance of difference 
at a significance value of p < 0.05.  
Secondary Efficacy Endpoints  
The group mean LMS difference between each Active Treatment Arm and the Vehicle 
Arm for the WOMAC stiffness, function and total  score at Day 35 will be tested for 
significance of difference at a significance value of p < 0.05 
Also, the group mean reduction in OA knee pain sc ore on a 100 mm VAS scale for 
each active treatment arm will be compared to the vehicle arm and tested for 
significance of difference at a significance value of p < 0.05 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 66 For dose-response estimation :  
The group mean LMS difference between the 5% and the 1% Active Treatment 
Arms for the WOMAC pain, stiffness, function and total  score at Day 35 will be 
tested for significance of difference at a significance value of p < 0.05 
Efficacy analyses will be carried out on the mITT set.  
9.5.3.1 Clinical Response  
Clinical response will be measured by reduction of WOMAC pain score . In order for a 
subject to be considered to have successfully obtained a clinical response, the following 
criteria must be met:  
WOMAC pain  score reduced to 50% or less of baseline at any of the stat ed 
assessment times.  
The durability of clinical response up to Day 94 will be evaluated by a tabulation of 
clinical response at a Day s 19, 35, 64, and the Day 94 visit by treatment group.  Subjects 
who have successfully met the above criteria (reduction of a least 50% in NRS pain 
score) at the Day 5 visit and who remain at least at this reduction of pain score or lower 
at the Day 35 visit will be considered to have a durable clinical response.  Subjects who 
at the Day 3 5 visit have less reduction in WOMAC in OAKP score than they did at the 
Day 5 assessment will be considered to have failed to achieve a durable clinical 
response.  
9.5.3.2 Exploratory Analyses  
Post hoc tests may be performed to test for differences in the eff icacy endpoints 
between the CGS -200-0 (Vehicle), CGS -200-1 and CGS-200-5 treatment groups for 
exploratory purposes.  
9.5.4 Tolerability Analyses  
The primary tolerability endpoint will be tolerability of the formulations on each of 
Days 1, 2, 3, and 4.  On each of these days, subjects will report an N RS score for 
burning / stinging at the application site pre -treatment and during treatment, and a 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 67 pre-treatment and during treatment pruritus score.  Pre-treatment and during treatment 
erythema and scaling scores will be recorded by clinic staff assigned to  the study.  This 
will be done at 0, 15, 30, 60, and 90 minutes after application to capture time points 
during treatment and after washing the application site.  The score for each of the abo ve 
tolerability variables will be entered as a value at each asses sment time. For each 
subject an ‚Äúarea under the curve‚Äù (AUC) calculation will be performed in 90 minute 
intervals for each score value.  The AUC‚Äôs for tolerability variables combined will be 
compared between the CGS -200-5 and CGS-200-0 treatment groups.  
9.5.5 Safety Analyses  
9.5.5.1 Adverse Events  
The incidence of all reported AEs and treatment -emergent AEs (TEAE) will be 
tabulated.  A TEAE is defined as an event that first occurs or worsens in intensity after 
the administration of study drug.  AEs will be classified by sys tem organ class and 
preferred term using the Medical Dictionary for Regulatory Activities (MedDRA).  The 
severity of the AE will be graded using the RCTC v2.0 whenever possible.  For AEs 
that are not included in the RCTC v2.0, the grading categories (mild, m oderate, severe, 
and life-threatening) will be used and equated to the respective RCTC grade (Grades 
1, 2, 3, and 4).  For incidence reporting, if a subject reports more than one AE that is 
coded to the same system organ class or preferred term, the subject  will be counted 
only once for that specific system organ class or preferred term.  
An overview of AEs, which includes subject incidence of TEAEs, treatment -related 
AEs, severity of AEs, SAEs, deaths, and AEs leading to discontinuation, will be 
presented.  For AEs presented by severity, the worst severity during the study will be 
presented for each subject.  The subject incidence of TEAEs will be summarized by 
system organ class and preferred term.  The subject incidence of treatment -related AEs 
and RCTC v2.0 toxicity grade will be summarized by preferred term.  
9.5.6 Vital Signs  
Descriptive summaries of the vital signs (both raw and change from baseline values) 
including blood pressure, heart rate, respiratory rate, and body temperature will be 
prepared for each dose  group. Descriptive statistics for quantitative variables will 
include sample size, mean, standard deviation, standard error, median, minimum, and 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 68 maximum.  The 95% confidence interval of the mean will be constructed if it is 
appropriate (when there is more than 1 subject in a cohort).  
Vital sign values will be classified as low, normal or high based on the cut -off points 
defined below, and the data will be summarized by presenting shift tables from baseline 
to each post -baseline visit.  For Baseline vita l sign measurements:  
Measurement  Lower Upper Unit 
Temperature  <35.0 >38.0 C  
Systolic Blood Pressure ( BP) <110 >135 mmHg 
Diastolic BP  <65 >85 mmHg 
Heart Rate  <50 >110 beats/min  
Respiratory Rate  <12 >20 breaths/min  
 
For Post-baseline vital sign measurements:  
Measurement (unit)  Low High 
Systolic Blood Pressure 
(mm Hg) > 20 point decrease from baseline  > 20 point increase from baseline  
Diastolic Blood 
Pressure (mm Hg)  >20 points decrease from baseline  > 20 point increase from baseline  
Pulse (beats per minute 
(bpm)) < 50 and decrease from baseline ‚â• 
15 > 100 and increase from baseline ‚â• 
15 
Temperature (C)  <35 >38 
Respiratory Rate 
(breaths per min)  <12 >20 
9.5.7 Interim Analyses  
Interim analys es will be performed at Days 19, 35, and 64 per 9.5.3 and 9.5.3.1 above, 
9.5.8 Procedures for Missing, Unused and Spurious Data  
Missing values will not be substituted by estimated values but  treated as missing in the 
statistical evaluation.  All data from all subjects dosed in the study will be included in 
all listings, plots, summary  tables, and statistical analyses when appropriate.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 69 9.5.9 Rules for Excluding Subjects from Analysis  
All dosed subjects will be included in the analyses of safety.  The sponsor will make 
any decisions regarding whether any subjects or any individual values belong ing to a 
subject will be excluded from the efficacy evaluations when the protocol violation is 
considered to have a negative impact on the scientific aspects and interpretation of the 
study results.  If the subject has received any study drug, all available  safety data will 
be used. The reason(s) for any exclusion will be described in the report.  
9.5.10 Procedures for Reporting Deviations from Original Statistical Plan  
Any deviations from the statistical analysis outlined in this protocol will be described, 
and reasons for the deviations listed, in the final Clinical Study Report.  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 70 10.0 CLINICAL STUDY ADMINISTRATION  
10.1 INFORMED CONSENT  
A copy of the proposed informed consent document must be submitted to the sponsor 
for review and comment prior to submission to the reviewing Institutional Review 
Board (IRB)/Independent Ethics Committee ( IEC). The consent form must be 
approved by the IRB/ IEC and contain all elements required by national, state, local and 
institutional regulations or requirements.  
The study will be completely explained to each prospective study subject.  Each subject 
found to be eligible for the study must voluntarily provi de written informed consent 
(including consent for the use and disclosure of research -related health information), 
using the IRB/IEC -approved consent form, prior to his or her enrollment in the study 
(i.e., before any protocol -dictated procedures that are not part of normal patient care 
are performed).  
10.2 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE 
REVIEW AND APPROVAL  
The investigator shall assure that an IRB/IEC, constituted in accordance with the 
International Conference on Harmonization ( ICH) Guideline for Good Clinical 
Practice ( GCP), will provide initial and continuing review of the study.  
The investigator should provide the sponsor with a list of IRB/IEC members or IRB 
assurance number.  Any documents that the IRB/IEC may need to fulfill its 
responsibilities, such as protocol amendments, and information concerning subject 
recruitment, payment or compensation procedures, or information from the sponsor 
will be submitted to the IRB/IEC.  The IRB/IEC‚Äôs written unconditional approval of the 
study pro tocol and the informed consent form will be in the possession of the 
investigator and the sponsor/designee, before the study is initiated.  The investigator 
will transmit the IRB/IEC‚Äôs unconditional approval statement to the sponsor/designee 
before study dr ug supplies are shipped to the site.  This approval must refer to the study 
by exact protocol title and number  and should identify the documents reviewed and the 
date of review.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 71 The Principal Investigator must inform the IRB/IEC of:  
‚Ä¢ Changes in informed cons ent 
‚Ä¢ Revisions of other documents originally submitted for review  
‚Ä¢ Serious and/or unexpected adverse events occurring during the study  
‚Ä¢ New information that may adversely affect the safety of subjects or the conduct 
of the study  
‚Ä¢ Annual update and/or request for re-approval 
‚Ä¢ Study completion  
10.3 PROTOCOL COMPLIANCE  
Except for a change that is intended to eliminate an apparent immediate hazard to a 
study subject, the protocol shall be conducted as described.  Any such change must be 
reported immediately to the sponso r and to the IRB/IEC.  
10.4 PROTOCOL REVISIONS  
Protocol amendments will be prepared and approved by the sponsor.  All protocol 
amendments will be signed by the investigator and submitted to the IRB/IEC for review 
prior to implementation.  Documentation of IRB/IEC approval must be forwarded to 
the sponsor.  If an amendment significantly alters the study design, increases potential 
risk to the subject or otherwise affects statements in the informed consent form, the 
informed consent form must be revised accordingly an d submitted to the IRB/IEC for 
review and approval.  The approved consent form must be used to obtain informed 
consent from new subjects prior to enrollment and must be used to obtain informed 
consent from subjects already enrolled if they are affected by t he amendment.  
10.5 DATA COLLECTION  
All data collected for each study subject will be entered in the eCRF developed in the 
Clinical Database and approved by the Sponsor.  The database will be 21 CFR Part 11 -
compliant.  The data system includes password protection and internal quality checks, 
such as automatic range checks, to identify data that appear inconsistent, incomplete, 
or inaccurate.  The investigator is responsible for maintaining the accuracy, 
completeness, legibility, and timeliness of the data reported.  All source documents 
should be completed in a neat, legible manner to ensure accurate interpretation of data.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 72 Data reported in the eCRF derived from source documents should be consistent with 
the source documents.  
The primary source document for this study  will be the subject‚Äôs medical record.  Data 
for the efficacy and tolerability variables will be recorded on a Data Sheet to be 
provided by Sponsor or designee and made part of the subject‚Äôs medical record.  The 
Data Sheet will be similar to a paper CRF and will serve as a ‚Äúhard copy‚Äù source 
document in case the eCRF becomes damaged or otherwise compromised. If the 
investigator(s) maintain separate research records, both the medical record and the 
research records will be considered the source documents for t he purposes of auditing 
the study.  
The anonymity of subjects must be maintained.  Subjects will be identified by their 
initials and an assigned subject number on eCRFs and other documents submitted to 
the sponsor.  Documents that identify the subject beyond initials and subject number 
will not be submitted to the sponsor (e.g.; the signed informed consent document) and 
must be maintained in strict confidence by the investigator, except to the extent 
necessary to allow auditing by the regulatory authorities, s tudy monitor, or sponsor 
representatives.  
Data recorded on source documents will be entered into eCRFs.  The investigator must 
promptly review the completed eCRFs for each subject.  A study monitor representing 
the sponsor will review the source documents against the eCRF on a regular basis 
through the study period as per the Study Monitoring Plan.   
Each eCRF will be electronically signed and dated by the Investigator.  
10.6 DATA MANAGEMENT RESPONSIBILITIES  
For data coding, the following medical diction aries will be used:  
‚Ä¢ AEs and concomitant diseases: MedDRA ; 
‚Ä¢ Concomitant medication: World Health Organization (WHO) ‚Äì Drug 
Visual and computerized methods of data validation will be applied in order to ensure 
accurate, consistent and reliable data for the subsequent statistical analysis.  These 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 73 procedures aim to detect out -of-range values, contradictory data, abnormal evolutions 
over time, and possible undetected protocol violations (eligibility criteria, time and 
medication compliance, etc.).  
Data Manageme nt and the study monitor will generate electronic queries for resolution 
by the site.  
The database will be locked in order to protect write access after the following 
preconditions are fulfilled:  
‚Ä¢ All data are entered in the database  
‚Ä¢ All data queries are re solved 
‚Ä¢ All necessary quality checks, in accordance with appropriate Standard Operating 
Procedures (SOPs), have been performed  
‚Ä¢ Decisions have been made and agreed as to the identities of all protocol violators  
‚Ä¢ All eCRFs have been source verified by the stud y monitor in the remote data 
capture (RDC)  
‚Ä¢ All eCRFs have been approved by the Investigator in the RDC system  
‚Ä¢ Written authorization from Vizuri Health Sciences is obtained.  
Upon completion of the study and resolution of all outstanding queries, Data 
Management will lock the database and generate the SAS datasets necessary for data 
analysis and reporting.  
The Data Management group will use the Clinical Database for storing and managing 
all data generated by this trial.  
10.7 STUDY MONITORING  
The study sponsor, Vi zuri Health Sciences, or its designee, will monitor the study.  
Study monitors representing the sponsor will visit study sites routinely throughout the 
trial. The sponsor/designee will review eCRFs and compare them with source 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 74 documents to verify accurate a nd complete collection of data and confirm that the study 
is being conducted according to the protocol.  Auditors representing the sponsor may 
also similarly evaluate the study and its monitors.  For these purposes, the investigator 
will make eCRFs and sourc e documents available when requested.  
In addition, the study may be evaluated by representatives of the regulatory authorities, 
who will also be allowed access to study documents.  The investigators should promptly 
notify Vizuri Health Sciences or its desig nee of any audits they have scheduled with 
any regulatory authority.  
The sponsor will promptly notify all investigators of all SAEs requiring expedited 
reporting that are considered unexpected and associated with the study drug.  The 
investigator must also report these AEs to the IRB/IEC responsible for reviewing the 
study. SAEs that are expected and unrelated to the study drug will be reported 
periodically.  
If Vizuri Health Sciences, its designee, the investigator, the IRB/IEC or regulatory 
authority discov er conditions arising during the study that indicate that the study should 
be halted or that the study center should be terminated, this action may be taken after 
appropriate consultation between Vizuri Health Sciences and the investigator.  
10.8 DRUG ACCOUNTABI LITY 
Upon receipt, the investigator is responsible for taking an inventory of the study drug.  
A record of this inventory must be kept and usage must be documented on study drug 
inventory forms provided by the Sponsor.  
10.9 RETENTION OF RECORDS  
The investigator shall retain records and source documents pertaining to the study, 
including any films, tracings, computer discs or tapes.  They will be retained for the 
longer of the maximum period required by the country and institution in which the 
study is conducted, o r the period specified by the sponsor at the time the study is 
completed, terminated or discontinued.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 75 If the investigator leaves the institution, the records shall be transferred to an 
appropriate designee who accepts the responsibility for the record rete ntion. Notice of 
such transfer shall be documented in writing and provided to the sponsor.  
10.10 FINANCIAL DISCLOSURE  
The investigator will provide Vizuri Health Sciences sufficient and accurate 
information on financial interests (proprietary or equity interests , payments exclusive 
of clinical trial costs) to allow complete disclosure to regulatory authorities.  The 
investigator shall promptly update this information if any relevant changes occur during 
the course of the investigation and for a period of one year following study completion.  
10.11 PUBLICATION POLICY  
Upon completion of the study, investigators are encouraged to publish the results in 
recognized scientific journals and at seminars or conferences.  For multi -center trials, 
no investigator will be authorized t o publish study results from an individual center 
until the earlier of the multi -center trial results are published or 12 months after the end 
or termination of the multi -center trial at all sites.  
A copy of all manuscripts and abstracts related to the study must be submitted to the 
sponsor for review and comment at least 30 days prior to submission for publication or 
for presentation at a scientific meeting.  Proposed abstracts and publications will be 
reviewed promptly.  The sponsor may delay publication  for up to 90 days to allow the 
filing of a patent application or for other important reasons.  The sponsor also reserves 
the right to delete from such materials any part or parts deemed to be confidential or 
proprietary.  
10.12 STUDY OR STUDY SITE TERMINATION  
If Vizuri Health Sciences, the investigator or regulatory authority discover conditions 
arising during the study that indicate that the study should be halted or that the study 
center should be terminated, this action may be taken after appropriate consultati on 
between Vizuri Health Sciences and the investigator.  Conditions that may warrant 
termination of the study include, but are not limited to, the following:  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 76 ‚Ä¢ The discovery of an unexpected, serious, or unacceptable risk to the subjects 
enrolled in the study  
‚Ä¢ A decision by the Sponsor to suspend or discontinue testing, evaluation, or 
development of the product  
The study site may warrant termination under the following conditions:  
‚Ä¢ Failure of the investigator to enroll subjects into the study at an acceptable ra te 
‚Ä¢ Failure of the investigator to comply with pertinent regulatory authority 
regulations  
‚Ä¢ Submission of knowingly false information from the research facility to Vizuri 
Health Sciences, study monitor, or the regulatory authority  
‚Ä¢ Insufficient adherence to pr otocol requirements  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 77 11.0 REFERENCES  
1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. 
Estimates of the prevalence of arthritis and other rheumatic conditions in the 
United States. Part I . Arthritis Rheum 2008;58(1):15 -25. 
2. Altman R, Asch E, Bloch  D, Bole G, Borenstein D, Brandt K, et al. 
Development of criteria for the classification and reporting of osteoarthritis. 
Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria 
Committee of the American Rheumatism Association . Arthritis Rheum 
1986;29(8):1039 -1049. 
3. Zhang W, Doherty M, Peat G, Bierma -Zeinstra MA, Arden NK, Bresnihan B, 
et al. EULAR evidence -based recommendations for the diagnosis of knee 
osteoarthritis . Ann Rheum Dis 2010;69(3):483 -489. 
4. Hochberg MC, Altman RD , April KT, Benkh alti M, Guyatt G, McGowan J, 
et al. American College of Rheumatology 2012 recommendations for the use of 
nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, 
hip, and knee . Arthritis Care Res (Hoboken) 2012;64(4):465 -474. 
5. Xu X, Dong B, Hsu C -H, Hu C, Lei C, Song J, et al. Physician/site staff 
assessments contribute to high placebo respnse in rheumatoid arthritis clinical 
trials [abstract 2594] . Arthritis Rheumatol 2016;68 (suppl 10) 2016 ACR/ARHP 
Annual Meeting.  
6. Bhugra D, Ventriglio A. Do cultures influence placebo response? Acta 
Psychiatr Scand 2015;132(4):227 -230. 
7. Babbar S, Marier JF, Mouksassi MS, Beliv eau M, Vanhove GF, Chanda S, et  al. 
Pharmacokinetic analysis of capsaicin after t opical administration of a 
high-concentration capsaicin patch to patients with peripheral neuropathic pain . 
Ther Drug Monit 2009;31(4):502 -510. 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 78 8. Woodworth T, Furst DE, Alten R, Bingham CO, 3rd, Yocum D, Sloan V, et al. 
Standardizing assessment and reporting of adverse effects in rheumatology 
clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0 . J 
Rheumatol 2007;34(6):1401 -1414. 
9. Draize JH, Woodard G, Calvery HO. Methods for the study of irritat ion and 
toxicity of substances applied topically to the skin and mucous membranes . 
Division of Pharmacology Food and Drug Administration, Federal Security 
Agency 1944.  
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 79 APPENDICES
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX A 
  
LABORATORY TESTS
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 81 APPENDIX A: LABORATORY TESTS  
Chemistry  Urinalysis  
Glucose pH 
Sodium Protein 
Potassium  Glucose 
Chloride Ketones 
Bicarbonate  Bilirubin 
Blood Urea Nitrogen (BUN)  Blood 
Creatinine  Urobilinogen  
Calcium Specific gravity  
Magnesium  Leucocytes  
Phosphorous ‚Äì inorganic   
Lactate Dehydrogenase (LDH)   
Total Protein  ACR OA criteria exclusions  
Albumin IgM-RF 
Alkaline Phosphatase (ALK)  ESR 
Total Bilirubin   
Alanine Transaminase (ALT)  Uric Acid  
Aspartate Transaminase (AST)   
Gamma-Glutamyl Transferase (GGT)   
Creatine Phosphokinase (CPK)  Pregnancy  
 Serum & Urine Pregnancy (Œ≤HCG)  
CBC with Automated Differential   
White Blood Cell Count (WBC)  Follicle-stimulating Hormone (FSH)  
Red Blood Cell Count (RBC)   
Hemoglobin (Hgb)   
Platelet Count   
Automated White Blood Cell 
Differential   
Neutrophils (% & absolute)   
Lymphocytes (% & absolute)   
Red Cell Indices   
Hematocrit   
MCV  
MCH  
MCHC  
  
  
  
  
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX B 
  
RHEUMATOLOGY COMMON TOXICITY CRITERIA V2 .0
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 83 APPENDIX B: RHEUMATOLOGY COMMON TOXICITY CRITERIA V2.0  
Rheumatology Common Toxicity Criteria v.2.0  
Based on Woodworth TG, et al., 2007.[8] Standardizing assessment of adverse effects in rheumatology clinical trials II. Status of OMERACT Drug Safety Working Group M ay 
2006: OMERACT 8. Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Cl inical Trials: Enabling Description of Comparative Safety Profiles for 
Antirheumatic Therapies  
 1-Mild 
Asymptomatic, or  
transient 
Short duration (<1 week)  
No change in life style  
No medication or OTC  2- Moderate  
Symptomatic  
Duration (1 -2 weeks)  
Alter lifestyle occasionally  
Meds relieve. (may be 
prescription),  
Study drug continued  3- Severe 
Prolonged symptoms, reversible, 
major functional impairment  
Prescription meds/ partial relief  
May be hospitalized <24hr 
Temporary study d rug 
discontinuation, or/and dose 
reduced 4- Includes Life Threatening  
At risk of death  
Substantial disability, especially if 
permanent.  
Multiple meds  
 
Hospitalized >24 hr  
 
Study drug discontinued  
A. ALLERGIC/IMMUNOLOGIC  
A1. Allergic 
reaction/hypersensitivity 
(includes drug fever)  Transient rash: drug fever  
<38¬∞C: transient, asymptomatic  
bronchospasm  Generalized urticaria 
responsive to meds; or drug 
fever > 38 ¬∞C, or reversible 
bronchospasm  Symptomatic bronchospasm 
requiring meds; symptomatic 
urticaria persisting with meds, 
allergy related 
oedema/angiodema  Anaphylaxis, 
laryngeal/pharyngeal oedema, 
requiring resuscitation  
A2. Autoimmune reaction  Serologic or other  
evidence of autoimmune 
reaction, but patient 
asymptomatic: all organ 
function normal and no 
treatment is required (e.g. 
vitiligo)  Evidence of autoimmune  
reaction involving a non -
essential organ or functions, 
requiring treatment other than 
immunosuppressiv e drugs (e.g. 
hypothyroidism)  Reversible autoimmune reaction 
involving function of a major 
organ or toxicity requiring short 
term immunosuppressive 
treatment (e.g. transient colitis or 
anaemia) Causes major organ dysfunction, 
or progressive, not reversible , or 
requires long term administration 
of high dose immunosuppressive 
therapy 
A3. Rhinitis  
(includes sneezing,  
nasal stuffiness, post  
nasal discharge)  Transient, non -prescription 
meds relieve  
 Prescription med. Required, 
slow 
 Corticosteroids or other 
prescription med. With persistent 
disabling symptoms such as 
impaired exercise tolerance  N/A 
 
A4. Serum sickness  Transient, non -prescription 
meds relieve  Symptomatic, slow response to 
meds (e.g. oral corticosteroids)  
 Prolonged; symptoms only 
partially relieved by meds; 
parenteral corticosteroids 
required Major organ dysfunction, requires 
long-term high -dose 
immunosuppressive therapy  
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 84  1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
A. ALLERGIC/IMMUNOLOGIC (CONT)  
A5. Vasculitis  Localized, not requiring 
treatment; or rapid response to 
meds; cutaneous  Symptomatic, slow response to 
meds (e.g. oral corticosteroids)  Generalized, parenteral 
corticosteroids required or/and 
short duration hospitalisation  Prolonged, hospitaliza tion, 
ischemic changes, amputation  
B. CARDIAC  
B1. Arrhythmia  Transient, asymptomatic  Transient, but symptomatic or 
recurrent, responds to meds  Recurrent/persistent; 
maintenance prescription  Unstable, hospitalization required; 
parenteral meds  
B2. Cardiac function    
Decreased  Asymptomatic decline in resting 
ejection fraction by  
> 10%, but < 20% of baseline 
value Asymptomatic decline of 
resting ejection fraction ‚â•20% 
of baseline value  CHF responsive to treatment  Severe or refractory CHF  
B3. Edema  Asymptomatic (e.g. 1 + 
feet/calves), self -limited, no 
therapy required  Symptomatic (e.g. 2 + 
feet/calves), requires therapy  Symptoms limiting function (e.g. 
3 + feet/calves, 2 + thighs), 
partial relief with treatment, 
prolonged  Anasarca; no response to 
treatment 
 
 
B4. Hypertension   
(new onset or worsening)  Asymptomatic, transient 
increase by > 20 mm Hg 
(diastolic) or to > 150/100 if 
previously normal, no therapy 
required Recurrent or persistent increase 
> 150/100 or by > 10 mm Hg 
(diastolic), requiring and 
responding readily to treatment  Symptomatic increase >150/100, 
> 20 mmHg, persistent, requiring 
multi-agent therapy, difficult to 
control Hypertensive crisis  
B5. Hypotension   
(without underlying diagnosis)  Transient, intermittent, 
asymptomat ic, orthostatic 
decrease in blood pressure > 20 
mm Hg Symptomatic, without 
interference with function, 
recurrent or persistent > 20 mm 
Hg decrease, responds to 
treatment  Syncope or symptomatic, 
interferes with function, 
requiring therapy and sustained 
medical attention, dose 
adjustment or drug 
discontinuation  
 
 
 
 
 
 
 
 Shock 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 85  1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
B. CARDIAC (CONT)  
B6. Myocardial ischaemia  Transient chest pain/ECG 
changes; rapid relief with nitro  Recurring chest pain, transient 
ECG ST-T changes; treatment 
relieves Angina with infarction, no or 
minimal functional compromise, 
reduce dose or discontinue study 
drug Acute myocardial infarction,  
arrhythmia and CHF  
B7. Pericarditis/ pericardial 
effusion Rub heard, asym ptomatic Detectable effusion by 
echocardiogram, symptomatic 
NSAID required  Detectable on chest X -ray, 
dyspnoea; or pericardiocentesis; 
requires corticosteroids  Pulsus alternates with low cardiac 
output; requires surgery  
B8. Phlebitis/thrombosis/ 
Embolism  
(excludes injection sites)  Asymptomatic, superficial, 
transient, local, or no treatment 
required Symptomatic, recurrent, deep 
vein thrombosis, no 
anticoagulant therapy required  Deep vein thrombosis requiring 
anticoagulant therapy  Pulmonary embolism  
C. GENERAL (constitutional)  
C1. Fatigue/malaise (asthenia)  Increase over baseline;  
most usual daily functions 
maintained,  
short term  Limits daily function 
intermittently over time  Interferes with basic ADL, 
persistent  Unable to care for self, bed or 
wheelchair bound > 50% of day 
debilitating, hospitalisation  
C2. Fever (pyrexia)  
(note: fever due to drug allergy 
should be coded as allergy)  Transient, few  
symptoms 37.7 -38.5¬∞C Symptomatic, recurrent 38.6 - 
39.9¬∞C. Relieved by meds  ‚â• 40¬∞C; ‚â§24h, persistent 
symptoms; partial response to 
meds. ‚â• 40¬∞C, debilitating, > 24h, 
hospitalization; no relief with 
meds 
C3. Headache  Transient or intermittent,  
no meds or relieved with OTC  Persistent, recurring, non -  
narcotic analgesics relieve  Prolonged with limited response 
to narcotic medicine  Intractable, debilitating, requires 
parenteral meds.  
C4. Insomnia  Difficulty sleeping, short term, 
not interfering with function  Difficulty sleeping  
Interfering with function, use of 
prescription med.  Prolonged sympto ms, with 
limited response to narcotic 
meds. Debilitating, hospitalization; no 
relief with meds  
C5. Rigors, chills  Asymptomatic, transient,  
no meds, or non -  
narcotic meds relieve  Symptomatic, narcotic meds 
relieve. Prolonged symptoms, with 
limited response to narcotic 
meds. Debilitating, hospitalization; no 
relief with meds  
C6. Sweating  
(diaphoresis)  Episodic, transient  Frequent, short term  Frequent, drenching, disabling  Dehydration, requiring IV 
fluids/hospitalization 24 hr  
C7. Weight gain  5-9.9% 10-19.9% 20-30% NA 
C8. Weight loss  5-9.9% 10-19.9% 20-30% NA 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 86  1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
D. DERMATALOGIC      
D1. Alopecia Subjective, transient  Objective, fully reversible  Patchy, wig used, partly 
reversible  Complete, or irreversible even if 
patchy 
D2. Bullous eruption  Localised, asymptomatic  Localised, symptomatic, 
requiring treatment  Generalized, responsive to 
treatment; reversible  Prolonged, generalized, or 
requiring hospitalization for 
treatment 
D3. Dry skin  Asymptomatic, controlled with 
emollients  Symptoms eventually (1 -2 wks 
controlled with emollient  Generalized, interfering with 
ADL >2 wks, persistent pruritus, 
partially responsive to treatment  Disabling for extended period, 
unresponsive to ancillary therapy 
and requiring study drug 
discontinuation for relief  
D4. Injection site reaction  Local erythema, pain, pruritus, < 
few days Erythema, pain, oedema, may 
include superficial phlebitis, 1 -
2 wks Prolonged induration, superfici al 
ulceration; includes thrombosis  Major ulceration necrosis 
requiring surgery  
D5. Petechiae (without 
vasculitis)  Few, transient asymptomatic  Dependent areas, persistent up 
to 2 wks Generalized, responsive to 
treatment; reversible  Prolonged, irreversible,  disabling 
 
D6. Photosensitivity  Transient erythema  Painful erythema and oedema 
requiring topical treatment  Blistering or desquamation, 
requires systematic 
corticosteroids  Generalized exfoliation or 
hospitalisation  
D7. Pruritus  Localised, asymptomatic,  
transient, local treatment  Intense, or generalized, relieved 
by systematic medication  Intense or generalized; poorly 
controlled despite treatment  Disabling, irreversible  
 
 
D8. Rash  
(not bullous)  Erythema, scattered 
macular/papul ar eruption; 
pruritus transient; TOC or no 
meds Diffuse macular/ 86papular 
eruption or erythema with 
pruritus; dry desquamation; 
treatment required  Generalized, moist  
desquamation, requires systemic 
corticosteroids; responsive to 
treatment; reversible  Exfoliative or ulcerating; or 
requires hospitalization; or 
parenteral corticosteroids  
D9. Induration/Fibrosis/ 
Thickening  
(not sclerodermal)  Localized, high density on 
palpation, reversible, no effect 
on ADL and not disfiguring  Local areas < 50% body 
surface, not disfiguring, 
transient interference with 
ADL, reversible  
 
 
 Generalized, disfiguring, 
interferes with ADL, reversible  Disabling, irreversible, systemic 
symptoms  
 
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 87  1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
E. EAR/NOSE/THROAT      
E1. Hearing loss  Transient, intermittent, no  
interference with function  Symptomatic, treatment 
required, reversible  Interferes with function;  
incomplete response to treatment  Irreversible deafness  
E2. Sense of smell  Slightly altered  Markedly altered  Complete loss, reversible  Complete loss, without recovery  
E3. Stomatitis  Asymptomatic  Painful, multiple, can eat  Interferes with nutrition, slowly 
reversible  Requires enteral support; residual 
dysfunction  
E4. Taste disturbance 
(dysgeusia)  Transiently altered; metallic  Persistently altered; limited 
effect on eating  Disabling, effect on nutrition  NA 
E5. Tinnitus  Intermittent, transient, no  
interference with function  Requires treatment, reversible  Disabling, or associated with 
hearing loss  Irreversible deafness  
 
E6. Voice changes  
(includes hoarseness, loss of 
voice, laryngitis  Intermittent hoarseness, able to 
vocalise Persistent hoarseness, able to 
vocalize Whispered speech, s low return 
of ability to vocalise  Unable to vocalize for extended 
period 
E7. Xerostomia  
(dry mouth)  Transient dryness  Relief with meds  Interferes with nutrition, slowly 
reversible  Extended duration interference 
with nutrition, requires parenteral 
nutrition 
F. EYE/OPHTHALMOLOGIC  
F1. Cataract  Asymptomatic, no change in 
vision, non -progressive  Symptomatic, partial visual loss, 
progressive  Symptoms impairing function, 
vision loss requiring treatment, 
including surgery  NA 
F2. Conjunctiviti s Asymptomatic, transient, rapid 
response to treatment  Symptomatic, responds to 
treatment, changes not 
interfering with function  Symptoms prolonged, partial 
response to treatment, interferes 
with function  NA 
F3. Lacrimation increased  
(tearing, watery eyes)  Symptoms not requiring 
treatment, transient  Symptomatic, treatment 
required, reversible  Unresponsive to treatment with 
major effect on function  NA 
F4. Retinopathy  Asymptomatic, non - progressive, 
no treatment  Reversible change in vision; 
readily responsive to treatment  Disabling change in vision 
ophthalmological findings 
reversible, sight improves over 
time Loss of sight  
  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 88   1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
F. EYE/OPHTHALMOLOGIC (CONT)  
F5. Vision changes  
(e.g. blurred, photophobia, night 
blindness, vitreous floaters)  Asymptomatic, transient, no 
treatment required  Symptomatic, vision changes 
not interfering with function, 
reversible  Symptomatic, vision changes 
interfering with function  Loss of sight  
F6. Xerophthalmia  
(dry eyes)  Mild scratchiness  Symptomatic without 
interfering with function, 
requires artificial tears  
 
 Interferes with vision/function, 
corneal ulceration  
 
 
 
 
 Loss of sight  
G. GASTROINTESTINAL  
G1. Anorexia  Adequate food intake, minimal 
weight loss  Symptoms requiring oral 
nutritional supplementation  Prolonged, requiring iv support  Requires hospitalization for 
nutritional support  
G2. Constipation  Asymptomatic, transient, 
responds to stool softener, OTC 
laxatives Symptomatic, requiring 
prescription laxatives, 
reversible  Obstipation requiring medical 
intervention  Bowel obstruction. Surgery 
required. 
G3. Diarrhea  Transient, increase of 2 -3 
stools/day over pre -treatment (no 
blood or mucus), OTC agents 
relieve Symptomatic, increase 4 -6 
stools/day, nocturnal stools, 
cramping, requires treatment 
with prescription meds.  Increase > 6 stools/day, 
associated with disabling 
symptoms, e.g. incontinence, 
severe cramping, partial 
response to treatment.  Prolonged, dehydration, 
unresponsive to treatment, requires 
hospitalization.  
G4. Dyspepsia  
(heartburn)  Transient, intermittent, responds 
to OTC antacids,  
H-2 blockers  Prolonged, recurrent, requires 
prescription meds, relieved by 
meds Persistent despite treatment, 
interferes with function, 
associated with GI bleeding  NA 
G5. GI bleed  
(gastritis, gastric or duodenal 
ulcer diagnosed -define 
aetiology)  Asymptomatic, endoscopic 
finding, haemocult + stools, no 
transfusion, responds rapidly to 
treatment Symptomatic, trans fusion ‚â§2 
units needed; responds to 
treatment  Haematemesis, transfusion 3 -4 
units, prolonged interference 
with function  Recurrent, transfusion > 4 units, 
perforation, requiring surgery, 
hospitalisation  
G6. Haematochezia  
(rectal bleeding)  Haemorrhodial,  
asymptomatic, no transfusion  Symptomatic, transfusion ‚â§2 
units, reversible  Recurrent, transfusion > 3 -4 
units > 4 units, hypotension, requiring 
hospitalisation  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 89  1- Mild 2- Moderate  3- Severe 4- Includes Life 
Threatening  
G. GASTROINTESTINAL (CONT)  
G7. Hepatitis  Laboratory abnormalities,  
asymptomatic, reversible  Symptomatic laboratory 
abnormalities, not 
interfering with function, 
slowly reversible  Laboratory abnormalities 
persistent >2 wks, symptoms 
interfere with function  Progressive, hepato -renal, 
anasarca, pre -coma or coma  
G8. Nausea, or nausea/vomiting  
(use diagnostic term)  Transient, intermittent, minimal 
interference with intake, rapid 
response to meds.  Persistent, recurrent, 
requires prescription meds, 
intake maintained  Prolonged, interferes with 
daily function and nutritional 
intake, periodic iv fluids  Hypotensive, 
hospitalization, parenteral 
nutrition, unresponsive to 
out-patient management  
G9. Pancreatitis  Amylase elevatio n, 
intermittent nausea/vomiting, 
transient, responds rapidly to 
treatment  Amylase elevation with 
abdominal pain, nausea, 
occasional vomiting, 
responsive to treatment  Severe, persistent abdominal 
pain with pancreatic enzyme 
elevation, incomplete or slow 
response to treatment  Complicated by shock, 
haemorrhage (acute 
circulatory failure)  
G10. Proctitis  Perianal pruritus, haemorrhoids 
(new onset), transient, or 
intermittent, relieved by OTC 
meds Tenesmus or ulcerations, 
anal fissure, responsive to 
treatment, m inimal 
interference with function  Unresponsive to treatment, 
marked interference with 
function Mucosal necrosis with 
haemorrhage, infection, 
surgery required  
H. MUSCULOSKELETAL      
H1. Avascular necrosis  Asymptomatic MRI changes, 
non-progressive  MRI changes and 
symptoms responsive to 
rest and analgesia  MRI changes, symptoms 
requiring surgical intervention  Wheelchair bound; surgical 
repair not possible  
H2. Arthralgia  Intermittent transient symptoms, 
no meds or relieved by OTC 
meds Persistent or recurrent 
symptoms, resolve with 
meds, little effect on 
function Severe symptoms despite 
meds impairs function  Debilitating, hospitalization 
required for treatment  
H3. Leg cramps  Transient, intermittent, does not 
interfere with function  Recurrent symptoms, 
minimally interferes with 
function or sleep, responds 
to meds Persistent, prolonged 
interference with function or 
sleep, partial or no response to 
meds NA 
H4. Myalgia  Occasional; does not interfere 
with function  Frequent, requires meds 
(non- narcotic); minor 
effects on function  Major change in 
function/lifestyle, narcotic 
pain meds  Debilitating, profound 
weakness, requires 
wheelchair, unresponsive to 
meds 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 90    1- Mild 2- Moderate 3- Severe 4- Includes Life Threatening  
I. NEUROPSYCHIATRIC  
I1. Anxiety or Depression 
(mood alteration)  Symptomatic, does not interfere 
with function; no meds  Frequent symptoms, responds 
to meds; interferes with ADL 
at times Persistent, prolonged 
symptoms, partial or no 
response to meds, limits daily 
function Suicidal ideation or danger to self  
I2. Cerebrovascular ischaemia  
 NA Single transient ischaemic 
event, responsive to treatment  Recurrent transient ischaemic 
events Cerebrovascular vascular accident 
with permanent disability 
I3. Cognitive disturbance  Subjective symptoms, transient, 
intermittent, not interfering with 
function Objective symptoms, 
persisting, interferes with daily 
function occasionally  Persistent, or worsening 
objective symptoms; interferes 
with routi ne daily routine  Debilitating/disabling and permanent; 
toxic psychosis  
 
 
I4. Depressed consciousness 
(somnolence)  Observed, transient, 
intermittent, not interfering with 
function 
 Somnolence or sedation, 
interfering with function  Persistent, progressive, 
obtundation, stupor  Coma 
I5. Inability to concentrate  Subjective symptoms, does not 
interfere with function  Objective findings, interferes 
with function  Persistent, prolonged objective 
findings or organic cause  NA 
I6. Insomnia  
(in absence of pain)  Occasional difficulty sleeping, 
transient intermittent, not 
interfering with function  Recurrent difficulty sleeping; 
requires meds for relief; 
occasional interference with 
function Persistent or worsening 
difficulty sleeping; severely 
interferes with routi ne daily 
function NA 
I7. Libido decreased  Decrease in interest  Loss of interest; influences 
relationship  Persistent, prolonged 
interfering with relationship  NA 
I8. Peripheral motor neuropathy  Subjective or transient loss of 
deep tendon reflexes; function 
maintained Objective weakness, 
persistent, no significant 
impairment of daily function  Objective weakness with 
substantial impairment of 
function Paralysis 
I9. Peripheral sensory 
neuropathy  
(sensory disturbance)  Subjective symptoms without 
objective findings, transient, not 
interfering with function  
 Objective sensory loss, 
persistent, not interfering with 
function Prolonged sensory loss or 
paraesthesias interfering with 
function NA 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 91    1- Mild 2- Moderate 3- Severe 4- Includes Life Threatening  
I. NEUROPSYCHIATRIC  (CONT) 
I10 Seizure  NA Recurrence of old seizures, 
controlled with adjustment of 
medication Recurrence/exacerbation with 
partial response to medication  Recurrence not controlled, 
requiring hospitalization;  new 
seizures 
I11 Vertigo  
(dizziness)  Subjective symptoms, transient, 
intermittent, no treatment  Objective findings, recurrent, 
meds relieve, occasionally 
interfering with function  Persistent, prolonged, 
interfering with daily function; 
partial response to medication  Debilitating without response to 
medication, hospitalisation  
J. PULMONARY  
J1. Asthma  Occasional wheeze, no 
interference with activities  Wheezing, requires oral meds, 
occasional interference with 
function Debilitating, requires nasa l 02 Requires ventilator assistance  
J2. Cough Transient, intermittent, 
occasional OTC meds relieve  Persistent, requires narcotic or 
other prescription meds for 
relief Recurrent, persistent coughing 
spasms without consistent relief 
by meds, interferes with  
function Interferes with oxygenation; 
debilitating  
J3. Dyspnea  Subjective, transient, no  
interference with function  Symptomatic, intermittent or 
recurring, interferes with 
exertional activities  Symptomatic during daily 
routine activities,  interferes with 
function, treatment with 
intermittent nasal 0 2 relieves Symptomatic at rest, debilitating, 
requires constant nasal 0 2 
J4. Pleuritic pain  
(pleurisy)  Transient, intermittent 
symptoms, no treatment or OTC 
meds relieve  Persistent symptoms, r equires 
prescription meds for relief  Prolonged symptoms, interferes 
with function, requires frequent 
narcotic pain relief  
 
 Debilitation, requiring 
hospitalisation  
J5. Pneumonitis (pulmonary 
infiltrates) Asymptomatic radiographic 
changes, transient, no treatment 
required Symptomatic, persistent, 
requiring corticosteroids  Symptomatic, requiring 
treatment including 02  Debilitating, not reversible; or  
requiring assisted ventilation  
J6. Pulmonary function 
decreased 
(FVC or carbon monoxide 
diffusion capacity ‚Äî 
DLCO) 76-90% of pre -treatment value  51-75% of pre -treatment value  26-50% of pre -treatment value  ‚â§25% of pre -treatment value  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 92   LABORATORY DATA  
K. HAEMATOLOGY  
 1- Mild 2- Moderate  3- Severe 4- Includes Life Threatening  
K1. Hgb (g/dl) decrease from 
pre-treatment  1.0-1.4 1.5-2.0 2.1-2.9, or Hgb<8.0, >7.0  ‚â• 3.0; or Hgb < 7.0  
K2. Leukopenia (total  
WBC) X 1000  3.0-3.9 2.0-2.9 1.0-1.9 < 1.0 
K3. Neutropenia  
(X 1000) 1.5-1.9 1.0-1.4 0.5-0.9 < 0.5 
K4. Lymphopenia  
(X 1000) 1.5-1.9 1.0-1.4 0.5-0.9 < 0.5 
K5. Platelets  
(X 1000) 75-LLN 50-74.9 20-49.9; platelet transfusion 
required < 20; recurrent platelet 
transfusions  
L. CHEMISTRY  
L1. Hypercalcaemia  
(mg/dl) 
  1.1 X ULN ‚Äî 11.5 11.6 ‚Äî 12.5 12.6 ‚Äî 13.5; or symptoms 
present > 13.5; or associated coma  
 
L2. Hyperglycemia  
(mg/dl) Fasting  140 ‚Äî 160 161 ‚Äî 250 251 ‚Äî 500  
> 500, or associated with  
ketoacidosis  
L3. Hyperkalaemia  
(mg/dl) 5.5 ‚Äì 5.9 6.0 ‚Äì 6.4 6.5 ‚Äì 7.0 or any ECG change  > 7.0 or any arrhythmia  
L4. Hypocalcaemia  
(mg/dl) 
 0.9 X LLN ‚Äì 7.8 
 7.7 ‚Äì 7.0 
 
 
 
 6.9 - 6.5; or associated with 
symptoms  < 6.5 or occurrence of tetany  
 
L5. Hypoglycemia  
(mg/dI) 
 55 ‚Äì 64 (no symptoms)  
 40 ‚Äì 54 (or symptoms present)  30 ‚Äì 39 (symptoms impair 
function)  
 30 or coma  
 
L6. Hyponatraemia -  
(mg/dI) 
 - 125 ‚Äì 129 
 120 ‚Äì 124 
 < 120 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 93  1- Mild 2- Moderate 3- Severe 4- Includes Life Threatening  
L. CHEMISTRY (CONT)  
L7. Hypokalaemia -  
(mg/dI) 
 - 3.0 ‚Äì 3.4 
2.0 -4.0 X ULN  2.5 ‚Äì 2.9 
4.0 X ULN with weakness but 
without life -threatening signs 
or symptoms  < 2.5 
> 4.0 X ULN with signs or 
symptoms of rhabdomyolysis or 
life-threatening  
L8. CPK (also if 
polymyositis -disease 1.2 ‚Äì 1.9 X ULN  2.0 ‚Äì 4.0 X ULN  > 4.0 X ULN with weakness 
but without life -threatening 
signs or symptoms  > 4.0 X ULN with signs or 
symptoms of rhabdomyolysis or 
life-threatening  
L9. Serum uric acid  1.2 ‚Äì 1.6 X ULN  1.7 ‚Äì 2.9 X ULN  3.0 ‚Äì 5.0 X ULN or gout  NA 
L10. Creatinine (mg/d1)  1.1-1.3 XULN  1.3 ‚Äì 1.8 X ULN  1. ‚Äì 3.0 X ULN  > 3.0 X ULN  
L11. SGOT (AST)  1.2 ‚Äì 1.5 X ULN  1.6 ‚Äì 3.0 X ULN  3.1 ‚Äì 8.0 X ULN  > 8.0 X ULN  
L12. SGPT (ALT)  1.2 ‚Äì 1.5 X ULN  1.6 ‚Äì 3.0 X ULN  3.1 ‚Äì 8.0 ULN > 8 X ULN 
L13. Alkaline  
Phosphatase  1.1 ‚Äì 2.0 X ULN  2.1 ‚Äì 3.0 X ULN  3.1 ‚Äì 5.0 X ULN  
 > 5.0 X ULN  
 
L14. T. bilirubin  1.1-1.4 XULN  1.5 ‚Äì 1.9 X ULN  2.0 ‚Äì 3.0 X ULN  > 3.0 X ULN  
L15. LDH  1.3 ‚Äì 2.4 X ULN  2.5 ‚Äì 5.0 X ULN  5.1 ‚Äì 10 X ULN  > 10 XULN  
M. URINALYSIS  
M1. Haematuria  Micro only  Gross, no clots  Clots, transfusion < 2 units  Transfusion required  
M2. Proteinuria (per 24 h)  300 ‚Äì 500 mg (tr/1+)  501 ‚Äì 1999 mg (2+)  2 ‚Äì 5.0 g (3+) nephritic 
syndrome  5.0 g (4+) anasarca  
M3. WBC in Urine  NA NA Indicating acute interstitial 
nephritis Associated with acute renal 
failure 
M4. Uric acid crystals  Present without symptoms  NA With stones or symptoms of 
stones (eg renal colic)  Causing renal outflow 
obstruction and hospitalization  
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX C 
  
SCHEDULE OF EVENTS
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 95 APPENDIX C: SCHEDULE OF EVENTS  
Assessment  SCR Treatment Days   Follow-up Period Days  
TIMEFRAME  Within 28  
days of Day 1  D1 D2 D3 D4 D5 
(Post Treat 
Day 1) D19¬± 3d  
(Post Treat 
Week 2) D35¬± 3d  
(Post Treat 
Week 4)  
D64¬± 3d  
(Post Treat 
Week 8)  
D94¬± 3d  
(Post Treat 
Week 12) Unscheduled, 
Early 
Termination, 
SAEl 
Clinic visit x x x x x x x x x x x 
Informed Consent  x           
Inclusion / Exclusion  x           
Demographics  x           
Medical & Medication History  x           
Randomization   x          
Physical exam  x          x 
Height and Weighta  x           
Vital Signsb x x x x x x    x x 
Knee X-raysc  x           
12-lead ECGd  x           
Clinical lab testse  x     x  x  x x 
Pregnancy or FSH Testf  x x          
Application Site Pain, Erythema, Scaling, 
Pruritus Assessmentg  x x x x x x x x x x x 
Exploratory Assessment of OA Knee Painh  x x          
VAS OA Knee Pain Assessmenti  x x x x x x x x x x 
WOMACj  x x    x x x x x x 
Drug administration   x x x x       
Assess. Of Concomitant Medicationsk  x x x x x x x x x x x 
AE Assessments   x x x x x x x x x x 
Study Exit          x  
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 96 Schedule of Events (Continued)   
a. Height and weight obtained at Screening.  
b. Vital signs include temperature, blood pressure, heart rate and respiratory rate. Performed at Screening, on Days 1 -4 at pre-dose and at 90 minutes (¬± 5 min) after applying study 
drug to knees, and at F ollow-up on Day 5  and 94. 
c. Knee X-rays of both knees must be obtained unless films/images performed within 6 months before screening. Copies of film and result s will be requested.  
d. Standalone 12 -lead ECG performed at Screening.  
e. Clinical laboratory tests incl ude (Appendix A): 
Hematology:  full blood count including RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, differential white cell count, platelet count (S creening, Day 5 , Day 35 and 
Day 94); 
Erythrocyte sed imentation rate (Screening only);  
Chemistry:  BUN, creatinine, uric acid, bilirubin (total), sodium, potassium, calcium, magnesium, phosphorous (inorganic), chloride, bica rbonate, ALK, AST (SGOT), ALT 
(SGPT), LDH, GGT, CPK, albumin, total protein, and gluco se (Screening, Day 5 , Day 35 and Day 94 ); 
IgM RF (Screening only);  
Urinalysis:  pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, specific gravity, leucocytes (Screening, Day 5 , Day 35 and Day 94 ). Clinically significant abnormal dipstick 
results will require microscopic analysis.  
f. Serum pregnancy test at Screening and urine pregnancy test at baseline on Day 1 for premenopausal women; FSH (follicle stimulating hormone) test at S creening to confirm 
postmenopausal status (females only) for up to 2 years after cessation of menses.  
g. Application site pain will be  assessed on NRS (0 -10); application site erythema/edema will be assessed using modified categorical Draize test (0 -3). Scaling and pruritus will 
also be scored on a similar categorical scale (0 -3). Scoring for application site pain (not related to knee p ain) will be performed on drug administration Days 1 -4 (pre-application 
[ÔÇ£ 30 min], and at 15 (¬± 5 min), 30 (¬± 5 min), 60 (¬± 5 min) and 90 minutes (¬± 5 min) after application) and on Days 5, 19, 35, 64 and 94. Application site skin reactions (erythema, 
edema, scaling, pruritus) will be assessed on drug administration Days 1 -4 at pre-application ( ÔÇ£ 30 min), and at  15 (¬± 5 min), 30 (¬± 5 min), 60  (¬± 5 min) and 90 minutes (¬±  5 min) 
after application), and on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/- 3 days), 35 (+/- 3 days), 64 (+/ - 3 days) and 94 (+/- 3 days). (Appendix E and Appendix F) 
h. Exploratory assessment of OA knee pain (average daily pain and daily w orst pain) at Screening and Day 1  (pre-application [ <30 min]) (Appendix D). 
i. OA Knee pain to be scored on 100 mm VAS scale ( Appendix G) pre-treatment (ÔÇ£ 30 min) on Days 1, 2, 3 and 4 and also on clinic visits at Days 5 (24 hrs [+/ - 4 hrs]), 
19 (+/- 3 days), 35 (+/- 3 days), 64 (+/ - 3 days) and 94 (+/- 3 days).  
j. WOMAC Pain, Stiffness, and Physical Function will be performed at Screening and on Day 1 prior to drug administration ( ÔÇ£ 30 min) and on Days 5 (24 hrs [+/ - 4 hrs]), 19 (+/- 
3 days), 35 (+/- 3 days), 64 (+/ - 3 days) and 94 (+/- 3 days). 
k. Document all medications taken within 90 days of the Screening Visit through Day 94. 
l. Refer to Section 6.5 for assessments to be completed at time o f SAE, early termination or unscheduled visit.  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX D 
  
EXPLORATORY ASSESSME NT OF OSTEOARTHRITIS  KNEE PAIN  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 98 APPENDIX D: EXPLORATORY ASSESSMENT OF OSTEOARTHRITIS KNEE PAIN  
Obtained at Screening  and pre-dose on Day 1 . 
 
On a scale from 0 to 10, with 0 being no pain at all and 10 being the worst pain imaginable, how 
would you rate your AVERAGE DAILY PAIN  
0 1 2 3 4 5 6 7  8 9 10  
No           Worst Pain   
Pain          Imaginable  
 
On the same scale, how would you rate your DAILY WORST PAIN  
0 1 2 3 4 5 6 7  8 9 10  
No           Worst Pain   
Pain          Imaginable  
 
 
 
 
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX E 
  
VAS OA KNEE PAIN  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 101 APPENDIX E: VAS OA Knee Pain  
Obtained on Days 1 -4: Pre-application ( < 30 min), and on Days 5, 19, 35, 64 and 94.  
 
VAS Pain Scale (100 mm)  
On the line below make a mark that represents your present level of pain for your RIGHT knee  
 
no pain              worst  
 pain imaginable  
On the line below make a mark that represents your present level of pain for your LEFT knee  
 
no pain              worst  
 pain imaginable  
 
 
 
 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX F 
  
ASSESSMENT O F BURNING / STINGING  PAIN 
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 103 APPENDIX F: ASSESSMENT OF BURNING / STINGING PAIN  
Obtained on Days 1 -4: Pre-application  (< 30 min) , and at 15 (+ 5 min), 30 (+ 5 min), 60 (+ 5 min), 
and 90 minutes (+ 5 min) after application, a nd on Days 5, 19, 35, 64 and 94.  
Assessment of Burning / Stinging Pain  
The question below refers  to BURNING OR STINGING PAIN  that you may be feeling right  now 
affecting the skin in the area around your  knees. 
On a scale from  0 to 10, with  0 being no pain at all  and 10 being the worst pain imaginable, how  
would you rate your  pain RIGHT  NOW in your RIGHT KNEE? (Please circle the number) 
0 1 2 3 4 5 6 7 8 9 10 
No                       Worst Pain  
Pain                        Imaginable   
 
On a scale from  0 to 10, with  0 being no pain at all  and 10 being the worst pain imaginable, how  
would you rate your  pain RIGHT  NOW in your LEFT KNEE? (Please circle the number) 
0 1 2 3 4 5 6 7 8 9 10 
No                        Worst Pain  
Pain                        Imaginable  
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 APPENDIX G 
  
ASSESSMENT OF SIGNS AND SYMPTOMS
CONFIDENTIAL  Vizuri Health Sciences LLC.  
 CGS-200-1 and CGS-200-5 vs. CGS-200-0 Vehicle  
Protocol VZU00025   
 
FINAL / Version 5.0 1-AUGUST -2018 Page 105 APPENDIX G: ASSESSMENT OF SIGNS AND SYMPTOMS  
Obtained on  Days 1 ‚Äì 4: Pre-application  (< 30 min), and at 15 (¬± 5 min), 30 (¬± 5 min), 60 (¬± 5 min), 
and 90 minutes (¬± 5 min) after  application, and on Days 5, 19, 35, 64 and 94. 
Assessment of Signs and Symptoms  
Right Knee  Left Knee  
Scaling (Circle Response):  Scaling (Circle Response):  
0 =  None: no evidence of scaling  0 =  None: no evidence of scaling  
1 =  Mild: mainly fine scales predominate  1 =  Mild: mainly fine scales predominate  
2 =  Moderate: somewhat coarser scales  2 =  Moderate: somewhat coarser scales  
3 =  Severe: coarse, thick scales; rough 
surface 3 =  Severe: coarse, thick scales; rough surface  
 
 
Erythema (Circle Response):  Erythema (Circle Response):  
0 =  None: no evidence of redness  0 =  None: no evidence of redness  
1 =  Mild: barely perceptible redness  1 =  Mild: barely perceptible redness  
2 =  Moderate: obvious redness, possible 
presence of edema  2 =  Moderate: obvious redness, possibl e 
presence of edema  
3 =  Severe: bright red, possible edema  3 =  Severe: bright red, possible edema  
 
 
Pruritus (Circle Response):  Pruritus (Circle Response):  
0 =  None: no itching  0 =  None: no itching  
1 =  Mild: occasional, slight itching  1 =  Mild: occasional, slight itching  
2 =  Moderate: frequent or constant itching; 
does not disturb sleep  2 =  Moderate: frequent or constant itching; 
does not disturb sleep  
3 =  Severe: bothersome itching; disturbs 
sleep 3 =  Severe: bothersome itching; disturbs sleep  
 
 
 